Document:

EX-10.1

 Exhibit 10.1 

1LIFE HEALTHCARE, INC. 

AMENDED AND RESTATED 

INVESTOR RIGHTS AGREEMENT 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	PAGE	 
	 SECTION 1. GENERAL
	  	 	2	 
			
	 1.1
	 	Amendment and Restatement of Prior Agreement	  	 	2	 
			
	 1.2
	 	Definitions	  	 	2	 
		
	 SECTION 2. RESTRICTIONS ON TRANSFER; REGISTRATION
	  	 	4	 
			
	 2.1
	 	Restrictions on Transfer	  	 	4	 
			
	 2.2
	 	Demand Registration	  	 	6	 
			
	 2.3
	 	Piggyback Registrations	  	 	7	 
			
	 2.4
	 	Form S-3 Registration	  	 	9	 
			
	 2.5
	 	Expenses of Registration	  	 	10	 
			
	 2.6
	 	Obligations of the Company	  	 	10	 
			
	 2.7
	 	Delay of Registration; Furnishing Information	  	 	13	 
			
	 2.8
	 	Indemnification	  	 	13	 
			
	 2.9
	 	Assignment of Registration Rights	  	 	16	 
			
	 2.10
	 	Limitation on Subsequent Registration Rights	  	 	16	 
			
	 2.11
	 	“Market Stand-Off” Agreement	  	 	16	 
			
	 2.12
	 	Agreement to Furnish Information	  	 	16	 
			
	 2.13
	 	Rule 144 Reporting	  	 	17	 
			
	 2.14
	 	Termination	  	 	17	 
		
	 SECTION 3. COVENANTS OF THE COMPANY
	  	 	17	 
			
	 3.1
	 	Basic Financial Information	  	 	17	 
			
	 3.2
	 	Inspection Rights	  	 	18	 
			
	 3.3
	 	Confidentiality of Records	  	 	19	 
			
	 3.4
	 	Stock Vesting	  	 	19	 
			
	 3.5
	 	Qualified Small Business Stock	  	 	19	 
			
	 3.6
	 	Proprietary Information and Inventions Agreements	  	 	20	 
			
	 3.7
	 	Termination of Covenants	  	 	20	 
		
	 SECTION 4. RIGHTS OF FIRST REFUSAL
	  	 	20	 
			
	 4.1
	 	Subsequent Offerings	  	 	20	 
			
	 4.2
	 	Exercise of Rights	  	 	20	 
			
	 4.3
	 	Issuance of Equity Securities to Other Persons	  	 	21	 
			
	 4.4
	 	Sale Without Notice	  	 	21	 
			
	 4.5
	 	Termination and Waiver of Rights of First Refusal	  	 	21	 
			
	 4.6
	 	Assignment of Rights of First Refusal	  	 	21	 

  
 i 

 TABLE OF CONTENTS 

(CONTINUED) 
  

							
	 	 	 	  	PAGE	 
	 4.7
	 	Excluded Securities	  	 	21	 
			
	 SECTION 5.
	 	MISCELLANEOUS	  	 	22	 
			
	 5.1
	 	Governing Law	  	 	22	 
			
	 5.2
	 	Successors and Assigns	  	 	22	 
			
	 5.3
	 	Entire Agreement	  	 	22	 
			
	 5.4
	 	Severability	  	 	22	 
			
	 5.5
	 	Amendment and Waiver	  	 	22	 
			
	 5.6
	 	Delays or Omissions	  	 	23	 
			
	 5.7
	 	Notices	  	 	23	 
			
	 5.8
	 	Attorneys’ Fees	  	 	23	 
			
	 5.9
	 	Titles and Subtitles	  	 	23	 
			
	 5.10
	 	Additional Investors	  	 	23	 
			
	 5.11
	 	Counterparts	  	 	24	 
			
	 5.12
	 	Aggregation of Stock	  	 	24	 
			
	 5.13
	 	Pronouns	  	 	24	 

  
 ii 

 1LIFE HEALTHCARE, INC. 

AMENDED AND RESTATED 

INVESTOR RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTOR RIGHTS
AGREEMENT (the “Agreement”) is entered into as of the 21st day of August, 2018, by and among 1LIFE HEALTHCARE, INC., a Delaware corporation (the
“Company”), and the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.” 

RECITALS 

WHEREAS, certain of the Investors are purchasing shares of the Company’s Series I Preferred Stock (the
“Series I Stock”) pursuant to that certain Series I Preferred Stock Purchase Agreement (the “Purchase Agreement”) of even date herewith (the “Financing”); 

WHEREAS, the obligations in the Purchase Agreement are conditioned upon the execution and delivery of this Agreement;

 WHEREAS, certain of the Investors (the “Prior Investors”) are holders of the Company’s
Series A Preferred Stock (the “Series A Stock”), Series B Preferred Stock (the “Series B Stock”), Series C Preferred Stock (the “Series C Stock”), Series D Preferred Stock
(the “Series D Stock”), Series E Preferred Stock (the “Series E Stock”), Series F Preferred Stock (the “Series F Stock”), Series G Preferred Stock (the “Series G Stock”) and Series
H Preferred Stock (the “Series H Stock” and together with the Series A Stock, Series B Stock, Series C Stock, Series D Stock, Series E Stock, Series F Stock, Series G Stock and Series I Stock, the “Preferred
Stock”); 
 WHEREAS, the Prior Investors and the Company are parties to an Amended and Restated Investor
Rights Agreement dated November 24, 2015 (the “Prior Agreement”); 

WHEREAS, the parties to the Prior Agreement desire to amend and restate the Prior Agreement
and accept the rights and covenants hereof in lieu of their rights and covenants under the Prior Agreement; and 

WHEREAS, pursuant to Section 5.5 of the Prior Agreement, such agreement may only be modified as set
forth herein by way of a written instrument signed by the Company and certain of the undersigned Investors, which this Agreement constitutes; and 

WHEREAS, in connection with the consummation of the Financing, the Company and the Investors have agreed to the
registration rights, information rights, and other rights as set forth below. 
 NOW, THEREFORE, in
consideration of these premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

 SECTION 1. GENERAL. 

1.1 Amendment and Restatement of Prior Agreement. The Prior Agreement is hereby amended in its entirety and restated herein. Such
amendment and restatement is effective upon the execution of this Agreement by the Company and the holders of sixty-five percent (65%) of the Registrable Securities held by the Prior Investors outstanding as of the date of this Agreement immediately
prior to the closing of the Financing. Upon such execution, all provisions of, rights granted and covenants made in the Prior Agreement are hereby waived, released and superseded in their entirety and shall have no further force or effect,
including, without limitation, all rights of first refusal set forth in Section 4 and any notice period associated therewith otherwise applicable to the transactions contemplated by the Purchase Agreement. 

1.2 Definitions. As used in this Agreement the following terms shall have the following respective meanings: 

(a) “Affiliate” of any Person means a Person that directly or indirectly, through one or more intermediaries, controls,
is controlled by or is under common control with the first mentioned Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is
controlled by one or more general partners or managing members of, or shares the same management company with, such Person or any investment fund, managed account vehicle, collective investment scheme or comparable investment vehicle
(“Fund”) now or hereafter existing that shares the same management company or registered investment advisor with such Person or any Fund now or hereafter existing that is controlled by, under common control with, managed or advised
by the same management company or registered investment advisor that controls, is under common control with, manages or advises the Fund that controls such Person. A Person shall be deemed to control another Person if such first Person possesses
directly or indirectly the power to direct, or cause the direction of, the management and policies of the second Person, whether through the ownership of voting securities, by contract or otherwise. 

(b) “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

(c) “Form S-3” means such form under the Securities Act as in
effect on the date hereof or any successor or similar registration form under the Securities Act subsequently adopted by the SEC which permits inclusion or incorporation of substantial information by reference to other documents filed by the Company
with the SEC. 
 (d) “Holder” means any person owning of record Registrable Securities that have not been sold to the
public or any assignee of record of such Registrable Securities in accordance with Section 2.9 hereof. 
 (e) “Initial
Offering” means the Company’s first firm commitment underwritten public offering of its Common Stock Registered under the Securities Act. 

(f) “Person” means an individual or group of individuals, a corporation, an association, a limited or general
partnership, a limited liability company, an estate, a trust, and any other entity or organization, governmental or otherwise. 
 (g)
“Register,” “registered,” and “registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the
declaration or ordering of effectiveness of such registration statement or document. 
 (h) “Registrable
Securities” means (a) Common Stock of the Company issuable or issued upon conversion of the Shares; (b) any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or
other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, such above-described securities; (c) any equity securities issued or issuable with respect to the Shares described in
clauses (a) or (b) above by 

  
 2 

 
way of combination of stock or shares, recapitalization, merger, consolidation or other reorganization and, for purposes of Sections 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.11, 2.12 and 2.13 only; and
(d) shares of Common Stock issued or issuable upon conversion of the Series C Stock, Series D Stock, Series E Stock and Series G Stock issued or issuable upon exercise of the Warrants. Notwithstanding the foregoing, Registrable Securities shall
not include any securities (i) sold by a person to the public either pursuant to a registration statement or Rule 144, (ii) sold in a private transaction in which the transferor’s rights under Section 2 of this Agreement are not
assigned or (iii) held by a Holder (together with its Affiliates) if the Company has completed its Initial Offering and all shares of Common Stock of the Company issuable or issued upon conversion of the Shares held by and issuable to such
Holder (and its Affiliates) can be immediately sold without registration in compliance with Rule 144 during any ninety (90) day period. 

(i) “Registrable Securities then outstanding” shall be the number of shares of the Company’s Common
Stock that are Registrable Securities and either (a) are then issued and outstanding or (b) are issuable pursuant to then exercisable, convertible and/or exchangeable securities. 

(j) “Registration Expenses” shall mean all expenses incurred by the Company in complying with
Sections 2.2, 2.3 and 2.4 hereof, including, without limitation, all registration and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company, reasonable fees and disbursements of a single special counsel
for the Holders, blue sky fees and expenses and the expense of any regular or special audits incident to or required by any such registration (but excluding the compensation of regular employees of the Company which shall be paid in any event by the
Company, underwriting discounts and commissions, stock transfer taxes, and fees of accountants for the Holders and additional counsel to the Holders). 

(k) “SEC” or “Commission” means the Securities and Exchange Commission. 

(l) “Securities Act” shall mean the Securities Act of 1933, as amended. 

(m) “Selling Expenses” shall mean all underwriting discounts and selling commissions applicable to the
sale. 
 (n) “Shares” shall mean the shares of the Company’s Series I Stock issued pursuant to the
Purchase Agreement (or in connection with the transactions contemplated thereby) and shares of the Company’s Series A Stock, Series B Stock, Series C Stock, Series D Stock, Series E Stock, Series F Stock, Series G Stock and Series H Stock held
from time to time by the Investors listed on Exhibit A hereto and their permitted assigns. 
 (o)
“Special Registration Statement” shall mean (i) a registration statement relating to any employee benefit plan or (ii) with respect to any corporate reorganization or transaction under Rule 145 of the Securities Act,
any registration statements related to the issuance or resale of securities issued in such a transaction or (iii) a registration related to stock issued upon conversion of debt securities. 

(p) “Warrants” shall mean (i) those certain warrants held by Silicon Valley Bank (A) dated February 26,
2010 to purchase shares of Series C Stock, (B) dated June 28, 2011 to purchase shares of Series D Stock, (C) dated January 29, 2013 to purchase shares of Series E Stock, and (D) dated January 26, 2015 to purchase shares
of Series G Stock; (ii) that certain warrant to purchase shares of Series G Stock held by Benchmark Capital Partners V, L.P. dated October 3, 2015; (iii) that certain warrant to purchase shares of Series G Stock held by Oak Investment
Partners XII, Limited Partnership dated October 5, 2015; (iv) that certain warrant to purchase shares of Series G Stock held by Maverick Fund II, Ltd. dated October 7, 2015; (v) that certain warrant to purchase shares of Series G Stock
held by GV 

  
 3 

 
2013, L.P. dated December 5, 2015; (vi) that certain warrant to purchase shares of Series G Stock held by DAG Ventures IV, L.P. dated October 12, 2015; (vii) that certain warrant to
purchase shares of Series G Stock held by DAG Ventures IV-QP, L.P. dated October 12, 2015; (viii) that certain warrant to purchase shares of Series G Stock held by Redmile Capital Offshore Fund II, Ltd.
dated October 14, 2015; (ix) that certain warrant to purchase shares of Series G Stock held by Redmile Private Investments I, LP dated October 14, 2015; (x) that certain warrant to purchase shares of Series G Stock held by Redmile Private
Investments I Affiliates, LP dated October 14, 2015; (xi) that certain warrant to purchase shares of Series G Stock held by Allen Partners Fund I LP dated October 28, 2015; (xii) that certain warrant to purchase shares of Series G Stock
held by Robert Lowe dated October 28, 2015; (xiii) that certain warrant to purchase shares of Series G Stock held by John Koski dated October 28, 2015; (xiv) that certain warrant to purchase shares of Series G Stock held by Dignity Health
dated November 4, 2015; and (xv) that certain warrant to purchase shares of Series G Stock held by Redmile Strategic Master Fund, LP, a Cayman Island limited partnership dated December 1, 2017. 

SECTION 2. RESTRICTIONS ON TRANSFER; REGISTRATION. 

2.1 Restrictions on Transfer. 

(a) Each Holder agrees not to make any sale, assignment, transfer, pledge or other disposition of all or any portion of the Shares or
Registrable Securities, or any beneficial interest therein, unless and until: 
 (i) there is then in effect a registration statement
under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or 

(ii) (A) The Holder has complied with all of the provisions of this Agreement and that certain Right of First Refusal and Co-Sale Agreement by and between the parties and dated as of the date hereof, (B) transferee has agreed in writing for the benefit of the Company to take and hold such Shares or Registrable Securities subject
to, and to be bound by, the terms of this Agreement, (C) such Holder shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed
disposition, and (D) if reasonably requested by the Company, such Holder shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such shares
under the Securities Act. It is agreed that the Company will not require opinions of counsel for transactions made pursuant to Rule 144, except in unusual circumstances, or for transfers to Affiliated entities. After its Initial Offering, the
Company will not require any transferee pursuant to Rule 144 to be bound by the terms of this Agreement or a statement of the circumstances surrounding the proposed disposition if the shares so transferred do not remain Registrable Securities
hereunder following such transfer. 
 (b) Notwithstanding the provisions of subsection (a) above: 

(i) no such restriction shall apply to a transfer by a Holder that is (A) a partnership transferring to its partners or former
partners in accordance with partnership interests or to the estate of any such partner or former partner or the transfer by gift, will or intestate succession of any partner to his or her spouse or to the siblings, lineal descendants or ancestors of
such partner or his or her spouse, (B) a corporation transferring to a wholly-owned subsidiary or a parent corporation that owns all of the capital stock of the Holder, (C) a limited liability company transferring to its members or former
members in accordance with their interest in the limited liability company, (D) an individual transferring to the Holder’s immediate family member or trust for the benefit of an individual Holder, (E) to an Affiliate or (F) to
the Company or another Holder; provided that in each case the transferee will agree in writing to be subject (to the extent not already subject) to the terms of this Agreement to the same extent as if he or she were an original Holder
hereunder; and 

  
 4 

 (ii) After the third anniversary of the Closing (as defined in the Purchase
Agreement), Carlyle Partners VII Holdings, L.P. (“Carlyle”) shall be entitled to sell or otherwise transfer all or part of its Shares or Registrable Securities to one or more unaffiliated third parties, provided that such transferee
will agree in writing to be subject (to the extent not already subject) to the terms of this Agreement to the same extent as if he, she or it were an original Holder hereunder. 

(c) Each certificate representing Shares or Registrable Securities shall (unless otherwise permitted by the terms of this Agreement) be
stamped or otherwise imprinted with legends substantially similar to the following (in addition to any legend required under applicable state securities laws): 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE
“ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT
TO REGISTRATION OR AN EXEMPTION THEREFROM. THE COMPANY MAY REQUIRE AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE
SECURITIES LAWS. 
 THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT
TO THE TERMS AND CONDITIONS OF A CERTAIN INVESTOR RIGHTS AGREEMENT BY AND BETWEEN THE STOCKHOLDER AND THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 

(d) The Company shall be obligated to reissue promptly unlegended certificates at the request of any Holder thereof if the Company has
completed its Initial Offering and the Holder shall have obtained an opinion of counsel (which counsel may be counsel to the Company) reasonably acceptable to the Company to the effect that the securities proposed to be disposed of may lawfully be
so disposed of without registration, qualification and legend, provided that the second legend listed above shall be removed only at such time as the Holder of such certificate is no longer subject to any restrictions hereunder (except
that the Company shall not require an opinion of counsel in connection with transfers to Affiliated entities or pursuant to Rule 144). 

  
 5 

 (e) Any legend endorsed on an instrument pursuant to applicable state securities laws
and the stop-transfer instructions with respect to such securities shall be removed upon receipt by the Company of an order of the appropriate blue sky authority authorizing such removal. 

2.2 Demand Registration. 

(a) Subject to the conditions of this Section 2.2, if the Company shall receive a written request from (x) beginning on the
earlier of (i) five (5) years after the date of this Agreement and (ii) six (6) months after the Company’s Initial Offering, the Holders of at least sixty-five percent (65%) of the Registrable Securities then outstanding (the
“Preferred Initiating Holders”) or (y) beginning six (6) months after the Company’s Initial Offering, Carlyle or any of its Affiliates holding Registrable Securities (the “Carlyle Initiating Holders”
and, together with the Preferred Initiating Holders, the “Initiating Holders”), in each case, that the Company file a registration statement under the Securities Act for an underwritten public offering with an anticipated aggregate
offering price in excess of $50,000,000, then the Company shall, within thirty (30) days of the receipt thereof, give written notice of such request to all Holders, and subject to the limitations of this Section 2.2, effect, as
expeditiously as reasonably possible, the registration under the Securities Act of all Registrable Securities that all Holders request to be registered. 

(b) All Holders proposing to distribute their securities pursuant to a registration under this Section 2.2 shall enter into an
underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by (i) the Holders of a majority of the Registrable Securities held by all Preferred Initiating Holders or (ii) the Carlyle
Initiating Holders, as applicable (which underwriter or underwriters, in each case, shall be reasonably acceptable to the Company). The right of any Holder to include its Registrable Securities shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein (unless otherwise mutually agreed by such Holder and (x) the Holders of a majority of the
Registrable Securities held by all Preferred Initiating Holders or (y) the Carlyle Initiating Holders, as applicable, with respect to such participation and inclusion). If a person who has requested inclusion in such registration as provided in
Section 2.2(a) does not agree to the terms of any such underwriting, such person shall be excluded therefrom by written notice from the Company, the underwriter or the applicable Initiating Holders. Notwithstanding any other provision of this
Section 2.2 or Section 2.4, if the underwriter advises the Company that marketing factors require a limitation of the number of securities to be underwritten (including Registrable Securities) then the Company shall so advise all Holders
of Registrable Securities that would otherwise be underwritten pursuant hereto, and (A) in the case of a registration requested by the Preferred Initiating Holders, the number of shares that may be included in the underwriting shall be
allocated to the Holders of such Registrable Securities on a pro rata basis based on the number of Registrable Securities held by all such Holders (including the Initiating Holders) or in such other proportion as shall be agreed by all
holders of Registrable Securities participating in the underwriting and (B) in the case of a registration requested by the Carlyle Initiating Holders, the number of shares that may be included in the underwriting shall be allocated first to the
Carlyle Initiating Holders and then to the Holders of such Registrable Securities on a pro rata basis based on the number of Registrable Securities held by all such Holders (excluding the Carlyle Initiating Holders) or in such other
proportion as shall be agreed by the Carlyle Initiating Holders and all other holders of Registrable Securities participating in the underwriting; provided, however, that the number of shares of Registrable Securities to be
included in such underwriting and registration shall not be reduced unless all other securities of the Company not included in the request by the Initiating Holders are first entirely excluded from the underwriting and registration. Any Registrable
Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration. For purposes of the provision in this Section 2.2(b) concerning apportionment, for any Holder that is a partnership, limited liability company, or
corporation, the partners, retired partners, members, retired members, stockholders, 

  
 6 

 
and Affiliates of such Holder, or the estates and immediate family members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the
foregoing Persons, shall be deemed to be a single “Holder”, and any pro rata reduction with respect to such “Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such
“Holder”, as defined in this sentence. 
 (c) The Company shall not be required to effect a registration pursuant to this
Section 2.2: 
 (i) after the Company has effected (x) two (2) registrations pursuant to this Section 2.2 at the
request of the Preferred Initiating Holders and (y) two (2) registrations pursuant to this Section 2.2 at the request of the Carlyle Initiating Holders, and such registrations have been declared or ordered effective and pursuant to which
securities have been sold (other than if the Holders elected not to sell securities pursuant to such registration); 
 (ii) during
the period starting with the date of filing of, and ending on the date one hundred eighty (180) days following the effective date of a registration statement pertaining to a public offering subject to Section 2.3, other than pursuant to a
Special Registration Statement; provided that the Company makes reasonable good faith efforts to cause such registration statement to become effective; 

(iii) if within thirty (30) days of receipt of a written request from Initiating Holders pursuant to Section 2.2(a), the
Company gives notice to the Holders of the Company’s intention to file a registration statement for a public offering subject to Section 2.3, other than pursuant to a Special Registration Statement within ninety (90) days of the
Company’s giving such notice; provided that the Company makes reasonable good faith efforts to cause such registration statement to become effective; 

(iv) if the Company shall furnish to Holders requesting a registration statement pursuant to this Section 2.2 a certificate signed
by the Chairman of the Board stating that, in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such registration statement to be effected at such time, in
which event the Company shall have the right to defer such filing for a period of not more than one hundred twenty (120) days after receipt of the request of the Initiating Holders; provided that such right to delay a request shall be
exercised by the Company not more than once in any twelve (12) month period; and provided, further that the Company shall not register any securities for the account of itself or any other stockholder during
such one hundred twenty (120) day period (other than pursuant to a Special Registration Statement); 
 (v) if the Initiating
Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.4 below; or 

(vi) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to
service of process in effecting such registration, qualification or compliance. 
 2.3 Piggyback Registrations. The Company shall
notify all Holders of Registrable Securities in writing at least fifteen (15) days prior to the filing of any registration statement under the Securities Act for purposes of a public offering of securities of the Company (including, but
not limited to, registration statements relating to secondary offerings of securities of the Company, but excluding Special Registration Statements and registration in connection with any consolidation, merger, or

  
 7 

 
reorganization, or with any employee benefit plan) and will afford each such Holder an opportunity to include in such registration statement all or part of such Registrable Securities held by
such Holder. Each Holder desiring to include in any such registration statement all or any part of the Registrable Securities held by it shall, within fifteen (15) days after the above-described notice from the Company, so notify the Company in
writing. If a Holder decides not to include all of its Registrable Securities in any registration statement thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include any Registrable Securities in any
subsequent registration statement or registration statements as may be filed by the Company with respect to offerings of its securities, all upon the terms and conditions set forth herein. 

(a) Underwriting. If the registration statement of which the Company gives notice under this Section 2.3 is for an
underwritten offering, the Company shall so advise the Holders of Registrable Securities. In such event, the right of any such Holder to include Registrable Securities in a registration pursuant to this Section 2.3 shall be conditioned upon
such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their Registrable Securities through such
underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Company. Notwithstanding any other provision of this Agreement, the Company and the underwriter may
in their discretion limit the number of shares to be underwritten, in which case the number of shares to be underwritten shall be allocated first to the Company and then to the Holders on a pro rata basis based on the total number of
Registrable Securities held by the Holders; provided, however, that no such reduction shall reduce the amount of securities of the selling Holders included in the registration below twenty-five percent (25%) of the total amount of
securities included in such registration, unless such offering is the Initial Offering and such registration does not include shares of any other selling stockholder, in which event any or all of the Registrable Securities of the Holders may be
excluded in accordance with the immediately preceding clause. In no event will shares of any other selling stockholder be included in such registration that would reduce the number of shares which may be included by Holders without the
written consent of Holders of a majority of the Registrable Securities proposed to be sold in the offering. If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company
and the underwriter, delivered at least ten (10) business days prior to the effective date of the registration statement. Any Registrable Securities excluded or withdrawn from such underwriting shall be excluded and withdrawn from the
registration. For any Holder which is a partnership, limited liability company or corporation, Affiliates of such Holder, partners, retired partners, members, retired members and stockholders of such Holder, or the estates and family members of any
such partners, retired partners, members and retired members and any trusts for the benefit of any of the foregoing Persons shall be deemed to be a single “Holder,” and any pro rata reduction with respect to such “Holder”
shall be based upon the aggregate amount of shares carrying registration rights owned by all Persons included in such “Holder,” as defined in this sentence. 

(b) Right to Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated by it
under this Section 2.3 whether or not any Holder has elected to include securities in such registration. The Registration Expenses of such withdrawn registration shall be borne by the Company in accordance with Section 2.5 hereof. 

  
 8 

 2.4 Form S-3 Registration. In case the
Company shall receive from any Holder of Registrable Securities a written request or requests that the Company effect a registration on Form S-3 (or any successor to Form S-3) or any similar short-form registration statement and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company will:

 (a) promptly give written notice of the proposed registration, and any related qualification or compliance, to all other
Holders of Registrable Securities; and 
 (b) as soon as practicable, effect such registration and all such qualifications and
compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together with all or such portion
of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company; provided,
however, that the Company shall not be obligated to effect any such registration, qualification or compliance pursuant to this Section 2.4: 

(i) after the Company has effected two (2) registrations pursuant to this Section 2.4 within the twelve (12) month
period preceding the date of such request, and such registrations have been declared or ordered effective; 
 (ii) if Form S-3 is not available for such offering by the Holders; 
 (iii) if the Holders, together
with the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than five million dollars
($5,000,000); 
 (iv) if within thirty (30) days of receipt of a written request from any Holder or Holders pursuant to this
Section 2.4, the Company gives notice to such Holder or Holders of the Company’s intention to make a public offering within ninety (90) days, other than pursuant to a Special Registration Statement; provided that the
Company makes reasonable good faith efforts to cause such registration statement to become effective; 
 (v) if the Company shall
furnish to the Holders a certificate signed by the Chairman of the Board of Directors of the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its
stockholders for such Form S-3 registration to be effected at such time, in which event the Company shall have the right to defer the filing of the Form S-3
registration statement for a period of not more than one hundred twenty (120) days after receipt of the request of the Holder or Holders under this Section 2.4; provided that such right to delay a request shall be exercised by the
Company not more than once in any twelve (12) month period; provided, further, that the Company shall not register any securities for the account of itself or any other stockholder during such one hundred twenty
(120) day period (other than pursuant to a Special Registration Statement); or 
 (vi) in any particular jurisdiction in which
the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance. 

(c) Subject to the foregoing, the Company shall file a Form S-3 registration statement
covering the Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the requests of the Holders. Registrations effected pursuant to this Section 2.4 shall not be counted as demands for
registration or registrations effected pursuant to Section 2.2. 

  
 9 

 2.5 Expenses of Registration. Except as specifically provided herein, all
Registration Expenses (inclusive of one counsel to the Holders not to exceed $30,000 and exclusive of underwriting discounts and commissions, stock transfer taxes, and fees of accountants for the Holders and additional counsel to the Holders)
incurred in connection with any registration, qualification or compliance pursuant to Sections 2.2, 2.3 or 2.4 herein shall be borne by the Company. All Selling Expenses incurred in connection with any registrations hereunder shall be borne by the
holders of the securities so registered and sold pro rata on the basis of the number of shares so registered and sold. The Company shall not, however, be required to pay for expenses of any registration proceeding begun pursuant to
Section 2.2 or 2.4, the request of which has been subsequently withdrawn by the applicable Initiating Holders unless (a) the withdrawal is based upon material adverse Company-specific information of which such Initiating Holders were not
aware at the time of such request, or (b) the Holders of a majority of Registrable Securities (or, in the case of a registration requested by the Carlyle Initiating Holders, the Carlyle Initiating Holders) agree to deem such registration to
have been effected as of the date of such withdrawal for purposes of determining whether the Company shall be obligated pursuant to Section 2.2(c)(i) to undertake any subsequent registration, in which event such right shall be forfeited by all
Holders (or, in the case of a registration requested by the Carlyle Initiating Holders, the Carlyle Initiating Holders). If the Holders are required to pay the Registration Expenses, such expenses shall be borne by the holders of securities
(including Registrable Securities) requesting such registration in proportion to the number of shares for which registration was requested. 

2.6 Obligations of the Company. Whenever required to effect the registration of any Registrable Securities, the Company shall, at its
expense and as expeditiously as reasonably possible: 
 (a) prepare and file with the SEC a registration statement with respect
to such Registrable Securities and use all reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration
statement effective for up to sixty (60) days or, if earlier, until the Holder or Holders have completed the distribution related thereto; provided, however, that at any time, upon written notice to the participating Holders and
for a period not to exceed sixty (60) days thereafter (the “Suspension Period”), the Company may delay the effectiveness of any registration statement or suspend the use or effectiveness of any registration statement (and the
applicable Initiating Holders hereby agree not to offer or sell any Registrable Securities pursuant to such registration statement during the Suspension Period) if the Company reasonably believes that there is or may be in existence material
nonpublic information or events involving the Company, the failure of which to be disclosed in the prospectus included in the registration statement could result in a Violation (as defined below); and, provided, further, that in the
case of any registration of Registrable Securities on Form S-3 which are intended to be offered on a continuous or delayed basis, such sixty (60) day period shall be extended to a period of one
(1) year. In the event that the Company shall exercise its right to delay or suspend the filing or effectiveness of a registration hereunder, the applicable time period during which the registration statement is to remain effective shall be
extended by a period of time equal to the duration of the Suspension Period. The Company may extend the Suspension Period for an additional consecutive sixty (60) days with the consent of the holders of a majority of the Registrable
Securities registered under the applicable registration statement, which consent shall not be unreasonably withheld. No more than two (2) such Suspension Periods shall occur in any twelve (12) month period. If so directed by the
Company, all Holders registering shares under such registration statement shall (i) not offer to sell any Registrable Securities pursuant to the registration statement during the period in which the delay or suspension is in effect after
receiving notice of such delay or suspension; and (ii) use reasonable efforts to deliver to the Company (at the Company’s expense) all copies, other than permanent file copies then in such Holders’

  
 10 

 
possession, of the prospectus relating to such Registrable Securities current at the time of receipt of such notice. Notwithstanding the foregoing, the Company shall not be required to file,
cause to become effective or maintain the effectiveness of any registration statement other than a registration statement on Form S-3 that contemplates a distribution of securities on a delayed or continuous
basis pursuant to Rule 415 under the Securities Act. Before filing a registration statement, the Company will furnish the Holders of Registrable Securities covered by such registration statement, the underwriters, if any, and any attorney,
accountant or other agent retained by any such Holders of Registrable Securities or underwriters copies of all such documents proposed to be filed, which documents will be subject to reasonable review and comment of such Holders, their counsel and
underwriters, if any, and will not file any registration statement to which the Holders of at least a majority of the Registrable Securities covered by such registration statement or the underwriter, if any, shall, for reasonable reasons, object.

 (b) Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in
connection with such registration statement as may be necessary to keep such registration statement effective or comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration
statement for the period set forth in subsection (a) above. 
 (c) Furnish to the Holders, without charge, such number of copies
of a prospectus including a preliminary prospectus, and any amendment of or supplement to the prospectus or any issuer free writing prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may
reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 
 (d) Use its reasonable efforts
to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders to keep such registration and qualification in effect
for so long as the registration statement remains in effect, and to take any other action which may be reasonably necessary or advisable to enable such Holder to consummate the disposition in such jurisdictions of the securities owned by such
Holder; provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions. 

(e) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual
and customary form, with the managing underwriter(s) of such offering. Except as otherwise provided herein, each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 

(f) Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto
is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in the light of the circumstances then existing. The Company will use reasonable efforts to amend or supplement such prospectus in
order to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the
circumstances then existing. 

  
 11 

 (g) Use its reasonable efforts to furnish, on the date that such Registrable
Securities are delivered to the underwriters for sale, if such securities are being sold through underwriters, (i) an opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration, in form and
substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and (ii) a letter, dated as of such date, from the independent certified public accountants of the Company, in form and
substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities. 

(h) Comply (and continue to comply) with all applicable rules and regulations of the SEC (including, without limitation, maintaining
disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f))
in accordance with the Exchange Act), and make generally available to its security holders, as soon as reasonably practicable after the effective date of the registration statement (and in any event within forty-five (45) days, or ninety
(90) days if it is a fiscal year, after the end of such twelve-month (12) period described hereafter), an earnings statement (which need not be audited) covering the period of at least twelve (12) consecutive months beginning with the
first day of the Company’s first calendar quarter after the effective date of the registration statement, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder. 

(i) (i) (A) cause all such Registrable Securities covered by such registration statement to be listed on the principal securities
exchange on which similar securities issued by the Company are then listed (if any), if the listing of such Registrable Securities is then permitted under the rules of such exchange, or (B) if no similar securities are then so listed, to either
cause all such Registrable Securities to be listed on a national securities exchange and, without limiting the generality of the foregoing, take all actions that may be required by the Company as the issuer of such Registrable Securities in order to
facilitate the managing underwriter’s arranging for the registration of at least two market makers as such with respect to such shares with FINRA, and (ii) comply (and continue to comply) with the requirements of any self-regulatory
organization applicable to the Company, including without limitation all corporate governance requirements. 
 (j) Provide and cause
to be maintained a transfer agent and registrar for all such Registrable Securities covered by such registration statement not later than the effective date of such registration statement. 

(k) Provide a CUSIP number for all Registrable Securities not later than the effective date of the registration statement. 

(l) Use its commercially reasonable efforts to make available its employees and personnel for participation in “road shows”
and other marketing efforts and otherwise provide reasonable assistance to the underwriters (taking into account the needs of the Company’s businesses and the requirements of the marketing process) in the marketing of Registrable Securities in
any underwritten offering. 
 (m) Use its commercially reasonable efforts to prevent the entry of any order suspending the
effectiveness of the registration statement and, in the event of the issuance of any such stop order, or of any order suspending or preventing the use of any related prospectus or suspending the qualification of any security included in such
registration statement for sale in any jurisdiction, the Company shall use its commercially reasonable efforts promptly to obtain the withdrawal of such order at the earliest possible time. 

  
 12 

 To the extent the Company is a well-known seasoned issuer (as defined in Rule 405 under the
Securities Act) (a “WKSI”) at the time any demand registration request is submitted to the Company pursuant to Section 2.4 above, and such demand registration request requests that the Company file an
automatic shelf registration statement (as defined in Rule 405 under the Securities Act) (an “automatic shelf registration statement”) on Form S-3, the Company shall file an automatic shelf
registration statement which covers those Registrable Securities which are requested to be registered. The Company shall use its commercially reasonable efforts to remain a WKSI (and not become an ineligible issuer (as defined in Rule 405 under the
Securities Act)) during the period during which such automatic shelf registration statement is required to remain effective. If the Company does not pay the filing fee covering the Registrable Securities at the time the automatic shelf registration
statement is filed, the Company agrees to pay such fee at such time or times as the Registrable Securities are to be sold. If the automatic shelf registration statement has been outstanding for at least three (3) years, at the end of the third
year the Company shall refile a new automatic shelf registration statement covering the Registrable Securities. If, at any time when the Company is required to re-evaluate its WKSI status, the Company
determines that it is not a WKSI, the Company shall use its commercially reasonable efforts to refile the shelf registration statement on Form S-3 and, if such form is not available, Form S-1 and keep such registration statement effective during the period during which such registration statement is required to be kept effective. 

If the Company files any shelf registration statement for the benefit of the holders of any of its securities other than the Holders, the
Company agrees that it shall include in such registration statement such disclosures as may be required by Rule 430B under the Securities Act (referring to the unnamed selling security holders in a generic manner by identifying the initial offering
of the securities to the Holders) in order to ensure that the Holders may be added to such shelf registration statement at a later time through the filing of a prospectus supplement rather than a post-effective amendment. 

2.7 Delay of Registration; Furnishing Information. 

(a) No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result
of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 
 (b) It shall be a
condition precedent to the obligations of the Company to take any action pursuant to Section 2.2, 2.3 or 2.4 that the selling Holders shall furnish to the Company such information regarding themselves, the Registrable Securities held by them
and the intended method of disposition of such securities as shall be required to effect the registration of their Registrable Securities. 

(c) The Company shall have no obligation with respect to any registration requested pursuant to Section 2.2 or Section 2.4 if
the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the number of shares or the anticipated aggregate offering price required to originally
trigger the Company’s obligation to initiate such registration as specified in Section 2.2 or Section 2.4, whichever is applicable. 

2.8 Indemnification. In the event any Registrable Securities are included in a registration statement under Section 2.2, 2.3 or
2.4: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, the partners, members,
officers and directors of each Holder, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any
losses, claims, damages, liabilities (joint or several), costs or expenses (or actions, proceedings or settlements in respect thereof) to which they may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar
as such losses, claims, damages, liabilities, costs or expenses (or actions, proceedings or settlements in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a
“Violation”) by the Company: (i) any untrue statement or alleged untrue 

  
 13 

 
statement of a material fact contained in such registration statement or incorporated by reference therein, including any preliminary prospectus, final prospectus or issuer free writing
prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or
(iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any other federal, state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any other federal,
state securities law in connection with the offering covered by such registration statement; and the Company will reimburse each such Holder, partner, member, officer, director, underwriter or controlling person for any legal or other expenses
reasonably incurred by them, as such expenses are incurred, in connection with investigating or defending any such loss, claim, damage, liability or action, as incurred; provided, however, that the indemnity agreement contained
in this Section 2.8(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor
shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished
expressly for use in connection with such registration by such Holder, partner, member, officer, director, underwriter or controlling person of such Holder. 

(b) To the extent permitted by law, each Holder will, if Registrable Securities held by such Holder are included in the securities as to
which such registration, qualifications or compliance is being effected, indemnify and hold harmless the Company, each of its directors, its officers and each person, if any, who controls the Company within the meaning of the Securities Act, any
underwriter and any other Holder selling securities under such registration statement or any of such other Holder’s partners, members, directors or officers or any person who controls such Holder, against any losses, claims, damages,
liabilities (joint or several), costs or expenses (or actions, proceedings or settlements in respect thereof) to which the Company or any such director, officer, controlling person, underwriter or other such Holder, or partner, member, director,
officer or controlling person of such other Holder may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages, liabilities, costs or expenses (or actions, proceedings or
settlements in respect thereof) arise out of or are based upon any of the following statements: (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement or incorporated by reference
therein, including any preliminary prospectus, final prospectus or issuer free writing prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be
stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act (collectively, a “Holder Violation”), in each case to the extent (and
only to the extent) that such Holder Violation occurs in reliance upon and in conformity with written information furnished by such Holder under an instrument duly executed by such Holder and stated to be specifically for use in connection with such
registration; and each such Holder will reimburse any legal or other expenses reasonably incurred by the Company or any such director, officer, controlling person, underwriter or other Holder, or partner, officer, director or controlling person of
such other Holder in connection with investigating or defending any such loss, claim, damage, liability or action if it is judicially determined that there was such a Holder Violation; provided, however, that the
indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be
unreasonably withheld; provided, further, that in no event shall any indemnity under this Section 2.8(b) exceed the net proceeds from the offering received by such Holder and such Holder will not be liable for any amount
paid in settlement of any such claim, loss, damage, liability or action if such settlement is effected without the written consent of such Holder, which consent shall not be unreasonably withheld, conditioned or delayed. 

  
 14 

 (c) Promptly after receipt by an indemnified party under this Section 2.8 of
notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8, deliver to the indemnifying party a
written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense
thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with the fees and expenses thereof to be paid by the indemnifying
party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel
in such proceeding or if the indemnified party shall have reasonably concluded that there may be reasonable defenses available to it which are different from or additional to those available to the indemnifying party. The failure to deliver written
notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8 to the extent, and only to the extent,
materially prejudicial to its ability to defend such action, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this
Section 2.8. 
 (d) If the indemnification provided for in this Section 2.8 is held by a court of competent jurisdiction to
be unavailable to an indemnified party with respect to any losses, claims, damages, liabilities, costs or expenses referred to herein, the indemnifying party, in lieu of indemnifying such indemnified party thereunder, shall to the extent permitted
by applicable law contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect (i) in the case of a Company-initiated registration under
Section 2.2, the relative benefits received by the Company on the one hand and the Holders whose Registrable Securities are included in the registration on the other hand, and (ii) in all cases, the relative fault of the indemnifying party
on the one hand and of the indemnified party on the other in connection with the Violation(s) or Holder Violation(s) that resulted in such loss, claim, damage, liability, cost or expense as well as any other relevant equitable considerations. The
relative fault of the indemnifying party and of the indemnified party shall be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material
fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided,
that (i) in no event shall any contribution by a Holder under this Section 2.8 (including any amounts paid by such Holder pursuant to Section 2.8(b)) exceed the net proceeds from the offering received by such Holder (ii) the
liability of each Holder to contribute as described herein shall be several and not joint, and (iii) no person or entity guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to
contribution from any person or entity who was not guilty of such fraudulent misrepresentation. 
 (e) Unless otherwise superseded by
an underwriting agreement entered into in connection with the underwritten public offering, the obligations of the Company and Holders under this Section 2.8 shall survive completion of any offering of Registrable Securities in a registration
statement and, with respect to liability arising from an offering to which this Section 2.8 would apply that is covered by a registration filed before termination of this Agreement, such termination. No indemnifying party, in the defense of any
such claim or litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such
indemnified party of a release from all liability in respect to such claim or litigation. 

  
 15 

 2.9 Assignment of Registration Rights. The rights to cause the Company to register
Registrable Securities pursuant to this Section 2 may be assigned by a Holder to a transferee or assignee of Registrable Securities (for so long as such shares remain Registrable Securities) that (a) is a partner, retired partner or
Affiliate of any Holder; (b) is a Holder’s family member or trust for the benefit of an individual Holder, or (c) holds at least one hundred thousand (100,000) shares of Registrable Securities (as adjusted for stock splits and
combinations) immediately after such transfer; provided, however, (i) the transferor shall, within ten (10) days after such transfer, furnish to the Company written notice of the name and address of such
transferee or assignee and the securities with respect to which such registration rights are being assigned and (ii) such transferee shall agree to be subject to all restrictions set forth in this Agreement. 

2.10 Limitation on Subsequent Registration Rights. After the date of this Agreement, the Company shall not enter into any agreement with
any holder or prospective holder of any securities of the Company that would grant such holder rights to demand the registration of shares of the Company’s capital stock, or to include such shares in a registration statement, unless, under the
terms of such agreement, such rights are subordinate to the rights of the Holders or are approved by a majority in interest of the Registrable Securities then outstanding. 

2.11 “Market Stand-Off” Agreement. Each Holder hereby agrees that such Holder shall
not sell, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any Common Stock (or other securities) of the Company held by such Holder
immediately prior to the effectiveness of the registration statement for such offering (other than those included in the registration or acquired in or following such registration) during the 180-day
period following the effective date of the Initial Offering (or such longer period, not to exceed 18 days after the expiration of the 180-day period, as the underwriter and the Company may request in order to
comply with applicable regulations), and that such Holder shall execute the standard lock-up agreement used in the Initial Offering; provided that all officers and directors of the Company and holders
of at least one percent (1%) of the Company’s voting securities are bound by and have entered into similar agreements. The obligations described in this Section 2.11 shall only apply to the Initial Offering and shall not apply to
(i) the sale of any shares to an underwriter pursuant to an underwriting agreement, (ii) a registration relating solely to employee benefit plans on Form S-1 or Form
S-8 or similar forms that may be promulgated in the future, or (iii) a registration relating solely to a transaction on Form S-4 or similar forms that may be
promulgated in the future. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply to all Holders subject to such agreements pro rata based on the number of shares
subject to such agreements, unless waived by a majority of the then-outstanding Registrable Securities. The Company covenants that any subsequent Holder of Registrable Securities will be bound by a market
stand-off agreement as defined in this Section 2.11. 
 2.12 Agreement to Furnish
Information. Each Holder agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter that are consistent with the Holder’s obligations under Section 2.11 or that are necessary to
give further effect thereto. In addition, if requested by the Company or the representative of the underwriters of Common Stock (or other securities) of the Company, each Holder shall provide, within ten (10) days of such request, such
information as may be reasonably required by the Company or such representative in connection with the completion of any public offering of the Company’s securities pursuant to a registration statement filed under the Securities Act. The
obligations described in Section 2.11 and this Section 2.12 shall not apply 

  
 16 

 
to a Special Registration Statement. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction until
the end of said day period. Each Holder agrees that any transferee of any shares of Registrable Securities shall be bound by Sections 2.11 and 2.12. The underwriters of the Company’s stock are intended third party beneficiaries of Sections
2.11 and 2.12 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 
 2.13
Rule 144 Reporting. With a view to making available to the Holders the benefits of certain rules and regulations of the SEC which may permit the sale of the Registrable Securities to the public without registration, the Company agrees to use its
best efforts to: 
 (a) Make and keep public information available, as those terms are understood and defined in SEC Rule 144 or
any similar or analogous rule promulgated under the Securities Act, at all times after the effective date of the first registration filed by the Company for an offering of its securities to the general public; 

(b) File with the SEC, in a timely manner, all reports and other documents required of the Company under the Exchange Act; and 

(c) So long as a Holder owns any Registrable Securities, furnish to such Holder forthwith upon request: a written statement by the
Company as to its compliance with the reporting requirements of said Rule 144 of the Securities Act, and of the Exchange Act (at any time after it has become subject to such reporting requirements); a copy of the most recent annual or quarterly
report of the Company filed with the Commission; and such other reports and documents as a Holder may reasonably request in connection with availing itself of any rule or regulation of the SEC allowing it to sell any such securities without
registration. 
 2.14 Termination. Sections 2.2-2.13 of this Agreement shall terminate
and be of no further force or effect upon the earliest of (i) the consummation of an Acquisition or Asset Transfer in which the holders of the Company’s capital stock receive cash or securities from a company subject to the reporting
requirements of Section 12 of the Exchange Act in exchange for their equity interest in the Company; (ii) the date that is five (5) years following the closing of the Qualified Public Offering; or (iii) with respect to a
particular Holder, such time as all Registrable Securities of such Holder may be sold pursuant to Rule 144 during any ninety (90) day period. Upon such termination, such shares shall cease to be “Registrable Securities” for all
purposes. 
 SECTION 3. COVENANTS OF THE COMPANY. 

3.1 Basic Financial Information. 

(a) So long as an Investor (with its Affiliates) shall own not less than 1,000,000 shares of Registrable Securities (as adjusted for
stock splits and combinations) (a “Major Investor”), the Company will furnish each Major Investor, as soon as practicable after the end of each fiscal year of the Company, and in any event within one hundred eighty (180) days
thereafter, a balance sheet of the Company, as at the end of such fiscal year, and a statement of income and a statement of cash flows of the Company, for such year, all prepared in accordance with United States generally accepted accounting
principles consistently applied (except as noted therein) and setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail. Such financial statements shall be accompanied by a report and opinion
thereon by independent public accountants selected by the Company’s Board of Directors including the directors elected by the holders of Series B Stock, Series C Stock, Series D Stock, Series E Stock, Series F Stock, Series G Stock and Series I
Stock. If the Company has any subsidiary whose accounts are consolidated with those of the Company for any period, then in respect of such period the financial statements delivered pursuant to this Section 3.1(a) shall be the consolidated and
consolidating financial statements of the Company and all such consolidated subsidiaries. 

  
 17 

 (b) The Company will furnish each Major Investor, as soon as practicable after the
end of the quarterly accounting periods in each fiscal year of the Company, and in any event within forty-five (45) days thereafter, a balance sheet of the Company as of the end of each such quarterly period, and a statement of income and a
statement of cash flows of the Company for such period and for the current fiscal year to date (with monthly detail and a statement of the Company’s headcount for each quarterly period if requested by an Investor), prepared in accordance
with United States generally accepted accounting principles consistently applied (except as noted therein), with the exception that no notes need be attached to such statements and year-end audit adjustments
may not have been made. If the Company has any subsidiary whose accounts are consolidated with those of the Company for any period, then in respect of such period the financial statements delivered pursuant to this Section 3.1(b) shall be the
consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 
 (c) The Company will
furnish each Major Investor, as soon as practicable after the end of each of the Company’s quarterly accounting periods in each fiscal year of the Company, and in any event within forty-five (45) days thereafter, a detailed capitalization
table of the Company, including a list of the Company’s outstanding convertible securities, which list shall include the face amount, issue date, maturity date, interest rate, conversion discount, change of control premium and valuation cap to
the extent applicable. 
 (d) The Company will furnish each Major Investor, as soon as practicable after the end of each month in each
fiscal year of the Company, and in any event within fifteen (15) days thereafter, a balance sheet of the Company as of the end of each such monthly period, and a statement of income and a statement of cash flows of the Company for such
monthly period and for the current fiscal year to date, prepared in accordance with United States generally accepted accounting principles consistently applied (except as noted therein), with the exception that no notes need be attached to such
statements and year-end audit adjustments may not have been made. If the Company has any subsidiary whose accounts are consolidated with those of the Company for any period, then in respect of such period the
financial statements delivered pursuant to this Section 3.1(d) shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

(e) The Company will furnish each Major Investor, as soon as practicable before the end of each fiscal year of the Company, and in any
event within thirty (30) days beforehand, a budget and business plan for the next fiscal year that has been approved by the Company’s Board of Directors. 

(f) The Company will furnish each Major Investor such other information relating to the financial condition, business prospects, or
corporate affairs of the Company as any Major Investor may from time to time reasonably request. 
 3.2 Inspection Rights. Each
Major Investor shall have the right to visit and inspect any of the properties of the Company or any of its subsidiaries, and to discuss the affairs, finances and accounts of the Company or any of its subsidiaries with its officers, and to review
such information as is reasonably requested all at such reasonable times and as often as may be reasonably requested; provided, however, that the Company shall not be obligated under this Section 3.2 with respect to a
competitor of the Company or with respect to information which the Board of Directors determines in good faith is confidential or attorney-client privileged and should not, therefore, be disclosed. 

  
 18 

 3.3 Confidentiality of Records. Each Investor agrees to use the same degree of
care as such Investor uses to protect its own confidential information to keep confidential any information furnished to such Investor pursuant to Section 3.1 or 3.2 hereof that the Company identifies as being confidential or proprietary (so
long as such information is not in the public domain), except that such Investor may disclose such proprietary or confidential information (i) to any director, officer, investment committee member, employee, investment adviser, agent or advisor
(including, without limitation, attorneys, accountants, consultants and financial advisors and other professionals) of such Investor (“Representative”) or general partner, actual or potential limited partner, member or other
Affiliate of such Investor or any Representative of any such Affiliate, as long as such Representative, general partner, limited partner, member or other Affiliate is advised of and agrees or has agreed to be bound by the confidentiality provisions
of this Section 3.3 or comparable restrictions; (ii) at such time as it enters the public domain through no fault of such Investor; (iii) that is communicated to it free of any obligation of confidentiality; (iv) that is
developed by Investor or its agents independently of and without reference to any confidential information communicated by the Company or its Representative; (v) as required by applicable law or regulation, regulatory body, stock exchange,
court or administrative order, or any listing or trading agreement applicable to such Investor; provided that, if it is reasonably practicable and legally permitted to do so, Investor gives the Company prompt written notice of such
requirement prior to such disclosure and Investor gives assistance in obtaining an order protecting the information from public disclosure; or (vi) as otherwise agreed by the Company in writing. 

3.4 Stock Vesting. Unless otherwise approved by the Board of Directors (including the directors elected by the holders of Series
B Stock, Series C Stock, Series D Stock, Series E Stock, Series F Stock, Series G Stock and Series I Stock), all stock options and other stock equivalents issued after the date of this Agreement to employees, directors, consultants and other service
providers shall be subject to (i) vesting as follows: (a) twenty-five percent (25%) of such stock shall vest at the end of the first year following such person’s services commencement date with the Company, and (b) seventy-five
percent (75%) of such stock shall vest over the remaining three (3) years; and (ii) a one hundred eighty (180) day lockup period in 

connection with the Company’s initial registered public offering of Equity Securities. The Company shall retain a right of first refusal on transfers
until the Company’s Initial Offering and the right to repurchase unvested shares at cost. 
 3.5 Qualified Small Business
Stock. The Company will use commercially reasonable efforts to comply with the reporting and record keeping requirements of Section 1202(d)(1)(C) of the Internal Revenue Code of 1986, as amended (the “Code”), and the
regulations thereunder, and during the one year period commencing on the initial Closing Date (as defined in the Purchase Agreement), the Company will not purchase any of its capital stock or permit any of its subsidiaries to purchase any of the
Company’s capital stock in excess of the limitations set forth in Section 1202(c) of the Code, so long as the Company’s Board of Directors determines that it is in the best interests of and not unduly burdensome to the Company to
comply with the provisions of Section 1202 of the Code. At the reasonable request of an Investor, the Company shall make a determination of whether the Shares (or their underlying Common Stock) constitute “qualified small business
stock” within the meaning of Sections 1045 and 1202 of the Code and shall advise such Investors in writing of such determination within ten (10) days of the receipt of such request. Pursuant to such request by the Investors, the Company
will provide information to support the “qualified small business stock” determination which may include financial statements, tax returns, and other documents that may be desired. 

  
 19 

 3.6 Proprietary Information and Inventions Agreements. The Company shall require all
employees and consultants with access to confidential information to execute and deliver a Proprietary Information and Inventions Agreement or Consulting Agreement, as applicable, in substantially the forms approved by the Company’s Board of
Directors. 
 3.7 Termination of Covenants. All covenants of the Company contained in Section 3 of this Agreement (other than the
provisions of Sections 3.4 and 3.7) shall expire and terminate as to each Investor upon the earlier of (i) the effective date of the registration statement pertaining to an Initial Offering that results in all of the then-outstanding shares of
Preferred Stock being converted into Common Stock or (ii) upon an “Asset Transfer” or “Acquisition,” each as defined in the Company’s Amended and Restated Certificate of Incorporation as in effect as of the date hereof,
in which the holders of the Company’s capital stock receive cash or publicly traded securities in exchange for their equity interest in the Company. 

SECTION 4. RIGHTS OF FIRST REFUSAL. 

4.1 Subsequent Offerings. Subject to applicable securities laws, (i) each Investor, so long as it holds Shares (or shares of Common
Stock issued upon conversion of such Shares), shall have a right of first refusal to purchase its pro rata share of all Equity Securities, as defined below, that the Company may, from time to time, propose to sell and issue after the date of
this Agreement, other than the Equity Securities excluded by Section 4.7 hereof (the “Offered Securities”) (in each case, that share of Offered Securities to which an Investor is entitled to subscribe is referred to herein as a
“Subscription Share”). An Investor’s pro rata share is equal to the ratio of (a) the number of shares of the Company’s Common Stock (including all shares of Common Stock issuable or issued upon conversion of
the Shares or upon the exercise of outstanding warrants or options) of which such Investor is deemed to be a holder immediately prior to the issuance of such Equity Securities to (b) the total number of shares of the Company’s outstanding
Common Stock (including all shares of Common Stock issued or issuable upon conversion of the Shares or upon the exercise of any outstanding warrants or options) immediately prior to the issuance of the Equity Securities. The term “Equity
Securities” shall mean (i) any Common Stock, Preferred Stock or other security of the Company, (ii) any security convertible into or exercisable or exchangeable for, with or without consideration, any Common Stock, Preferred Stock
or other security (including any option to purchase such a convertible security), (iii) any security carrying any warrant or right to subscribe to or purchase any Common Stock, Preferred Stock or other security or (iv) any such warrant or
right. 
 4.2 Exercise of Rights. If the Company proposes to issue any Equity Securities, it shall give each Investor written notice
of its intention, describing the Equity Securities, the price and the terms and conditions upon which the Company proposes to issue the same. Each Investor shall have twenty (20) days from the giving of such notice to agree to purchase
up to its applicable Subscription Share of the Equity Securities for the price and upon the terms and conditions specified in the notice by giving written notice to the Company and stating therein the quantity of Equity Securities to be purchased.
The Company shall promptly, in writing, inform each Investor that elects to purchase all the shares available to it (a “Fully-Exercising Investor”) of any other Investor’s failure
to do likewise. During the ten (10) day period commencing after such information is given, each Fully-Exercising Investor may elect to purchase a portion of the then unsubscribed Offered Securities. Each
Fully-Exercising Investor will have the right to purchase up to its Oversubscription Share of the unsubscribed Offered Securities. Notwithstanding the foregoing, the Company shall not be required to offer or sell such Equity Securities to any
Investor who would cause the Company to be in violation of applicable federal securities laws by virtue of such offer or sale. For purposes hereof, a Fully-Exercising Investor’s “Oversubscription Share” is equal to the ratio of
(a) the number of shares of the Company’s Common Stock (including all shares of Common Stock issuable or issued upon conversion of the Shares or upon the exercise of outstanding warrants or options) 

  
 20 

 
of which such Fully-Exercising Investor is deemed to be a holder immediately prior to the issuance of such Equity Securities to (b) the total number of shares of the Company’s Common
Stock (including all shares of Common Stock issued or issuable upon conversion of the Shares or upon the exercise of any outstanding warrants or options) deemed to be held by all Fully-Exercising Investors immediately prior to the issuance of the
Equity Securities. An Investor shall be entitled to apportion the right to purchase Offered Securities hereby granted to it among itself and its Affiliates in such proportions as it deems appropriate. The failure by any Holder to exercise its option
to purchase Offered Securities with respect to one offering, sale or issuance shall not affect its option to purchase Offered Securities in any subsequent offering, sale or issuance. 

4.3 Issuance of Equity Securities to Other Persons. The Company shall have sixty (60) days thereafter to sell the Equity Securities
in respect of which the Investors’ rights were not exercised, at a price and upon general terms and conditions not materially more favorable to the purchasers thereof than specified in the Company’s notice to the Investors pursuant to
Section 4.2 hereof. If the Company has not sold such Equity Securities within sixty (60) days of the notice provided pursuant to Section 4.2, the Company shall not thereafter issue or sell any Equity Securities, without first offering
such securities to the Investors in the manner provided above. 
 4.4 Sale Without Notice. In lieu of giving notice to the Investors
prior to the issuance of Equity Securities as provided in Section 4.2, the Company may elect to give notice to the Investors within thirty (30) days after the issuance of Equity Securities. Such notice shall describe the type, price and
terms of the Equity Securities. Each Investor shall have twenty (20) days from the date of receipt of such notice to elect to purchase up to the number of shares that would maintain such Investor’s pro rata share of the
Company’s equity securities after giving effect to such issuance. The closing of such sale shall occur within sixty (60) days of the date of notice to the Investors. The Company shall promptly, in writing, inform each Fully-Exercising
Investor that elects to purchase all the shares available to it of any other Investor’s failure to do likewise. During the ten (10) day period commencing after such information is given, each Fully-Exercising Investor may elect to up to
its Oversubscription Share of the unsubscribed Equity Securities. Notwithstanding the foregoing, the Company shall not be required to offer or sell such Equity Securities to any Investor who would cause the Company to be in violation of applicable
federal securities laws by virtue of such offer or sale. 
 4.5 Termination and Waiver of Rights of First Refusal. The rights of first
refusal established by this Section 4 shall not apply to, and shall terminate upon the earlier of (i) the effective date of a “Qualified Public Offering,” as defined in the Company’s Amended and Restated Certificate
of Incorporation, as may be amended from time to time, or (ii) the consummation of an Acquisition or Asset Transfer. 
 4.6
Assignment of Rights of First Refusal. The rights of first refusal of each Investor under this Section 4 may be assigned to the same parties, subject to the same restrictions as any transfer of registration rights pursuant to
Section 2.9. 
 4.7 Excluded Securities. The rights of first refusal established by this Section 4 shall have no application
to any of the Equity Securities (i) that are excluded as “Additional Shares of Common Stock” pursuant to Article IV(D)(5)(h)(viii) of the Company’s Amended and Restated Certificate of Incorporation, as may be amended from time to
time, and (ii) that are issued by the Company pursuant to the terms of Section 2.4 of the Purchase Agreement. 

  
 21 

 SECTION 5. MISCELLANEOUS. 

5.1 Governing Law. This Agreement shall be governed by and construed under the laws of the State of Delaware, without reference to
conflicts of laws or principles thereof. Any controversy between the parties hereto involving any claim arising out of or relating to the termination of this Agreement, will be submitted to and be settled by final and binding arbitration in San
Francisco County, in accordance with the then current Commercial Arbitration Rules of the American Arbitration Association (the “AAA”), and judgment upon the award rendered by the arbitrators may be entered in any court having
jurisdiction thereof. Such arbitration shall be conducted by three (3) arbitrators chosen by the Company and the Purchasers, or failing such agreement, an arbitrator appointed by the AAA. There shall be limited discovery prior to the
arbitration hearing as follows: (a) exchange of witness lists and copies of documentary evidence and documents relating to or arising out of the issues to be arbitrated, (b) depositions of all party witnesses and (c) such other
depositions as may be allowed by the arbitrators upon a showing of good cause. Depositions shall be conducted in accordance with the California Code of Civil Procedure, the arbitrator shall be required to provide in writing to the parties the basis
for the award or order of such arbitrator, and a court reporter shall record all hearings, with such record constituting the official transcript of such proceedings. 

5.2 Successors and Assigns. Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be
binding upon, the parties hereto and their respective permitted successors, assigns, heirs, executors, and administrators and shall inure to the benefit of and be enforceable by each person who shall be a holder of Registrable Securities from time
to time; provided, however, that prior to the receipt by the Company of adequate written notice of the transfer of any Registrable Securities specifying the full name and address of the transferee, the Company may deem and treat
the person listed as the holder of such shares in its records as the absolute owner and holder of such shares for all purposes, including the payment of dividends or any redemption price. 

5.3 Entire Agreement. This Agreement, the Exhibits and Schedules hereto, the Purchase Agreement and the other documents delivered
pursuant thereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and no party shall be liable or bound to any other in any manner by any oral or written representations, warranties,
covenants and agreements except as specifically set forth herein and therein. Each party expressly represents and warrants that it is not relying on any oral or written representations, warranties, covenants or agreements outside of this Agreement.

 5.4 Severability. In the event one or more of the provisions of this Agreement should, for any reason, be held to be invalid,
illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never
been contained herein. 
 5.5 Amendment and Waiver.  

(a) Except as otherwise expressly provided, this Agreement may be amended or modified, and the obligations of the Company and the rights
of the Holders under this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only upon the written consent of the Company and the holders of a majority of the then-outstanding
Registrable Securities; provided however that this Agreement shall not be amended without the consent of each Holder or Investor adversely affected if such amendment would modify the rights or obligations of that Holder
or Investor as compared to the rights and obligations of the other Holders or Investors (i.e., if an amendment did not alter ratably the rights and obligations of the Holders or the Investors hereunder); and provided,
further, that notwithstanding the foregoing, Sections 2.14, 3.7 and 5.5 of this Agreement shall not be amended or waived without the written consent of each of Oak Investment Partners XII, Limited Partnership, and GV 2013, L.P., and
Redmile Capital Offshore Fund II, Ltd. and its Affiliates; and 

  
 22 

 
provided, further, that notwithstanding the foregoing, Sections 2.11 and 3.1 of this Agreement shall not be amended or waived without the written consent of Fidelity Select
Portfolios: Health Care Portfolio, Fidelity Select Portfolios: Medical Equipment and Systems Portfolio, Fidelity Central Investment Portfolios LLC: Fidelity Health Care Central Fund, Fidelity Advisor Series VII: Fidelity Advisor Health Care Fund,
and Variable Insurance Products Fund IV: Health Care Portfolio; and provided, further, that notwithstanding the foregoing, the rights of holders of Series H Preferred Stock pursuant to Section 4 hereof may be waived (and this
proviso may be amended) only upon the written consent of the holders of a majority of the then-outstanding Series H Preferred Stock; and provided, further, that notwithstanding the foregoing, Sections 2.1(b)(ii), 2.2(a), 2.11, 2.14,
3.1, 3.7 and 5.5 of this Agreement shall not be amended or waived without, and the rights of holders of Series I Preferred Stock pursuant to Section 4 hereof may be waived (and this proviso may be amended) only upon, in each case, the written
consent of Carlyle. 
 (b) For the purposes of determining the number of Holders or Investors entitled to vote or exercise any rights
hereunder, the Company shall be entitled to rely solely on the list of record holders of its stock as maintained by or on behalf of the Company. 

5.6 Delays or Omissions. It is agreed that no delay or omission to exercise any right, power, or remedy accruing to any party, upon any
breach, default or noncompliance by another party under this Agreement shall impair any such right, power, or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or of any
similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent, or approval of any kind or character on any party’s part of any breach, default or noncompliance under the Agreement or any
waiver on such party’s part of any provisions or conditions of this Agreement must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement, by law, or otherwise
afforded to any party, shall be cumulative and not alternative. 
 5.7 Notices. All notices required or permitted hereunder shall be
in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the
next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying
next day delivery, with written verification of receipt. All communications shall be sent to the party to be notified at the address as set forth on the signature pages hereof or Exhibit A hereto or at such other address or electronic mail
address as such party may designate by ten (10) days advance written notice to the other parties hereto. 
 5.8 Attorneys’ Fees.
In the event that any suit or action is instituted under or in relation to this Agreement, including without limitation to enforce any provision in this Agreement, the prevailing party in such dispute shall be entitled to recover from the losing
party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without
limitation, all fees, costs and expenses of appeals. 
 5.9 Titles and Subtitles. The titles of the sections and subsections of this
Agreement are for convenience of reference only and are not to be considered in construing this Agreement. 
 5.10 Additional
Investors. Notwithstanding anything to the contrary contained herein, if the Company shall issue additional shares of its Series I Stock, any purchaser of such shares of Series I Stock shall become a party to this Agreement by executing and
delivering an additional counterpart signature page to this Agreement and shall be deemed an “Investor,” a “Holder” and a party hereunder. 

  
 23 

 5.11 Counterparts. This Agreement may be executed in any number of counterparts, each
of which shall be an original, but all of which together shall constitute one instrument. 
 5.12 Aggregation of Stock. All shares of
Registrable Securities held or acquired by Affiliated entities or persons or persons or entities under common management or control shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

5.13 Pronouns. All pronouns contained herein, and any variations thereof, shall be deemed to refer to the masculine, feminine or
neutral, singular or plural, as to the identity of the parties hereto may require. 
 [THIS SPACE INTENTIONALLY LEFT BLANK] 

  
 24 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	COMPANY:
	
	1LIFE HEALTHCARE, INC.
		
	By:	 	 /s/ Amir Dan Rubin

		 	AMIR DAN RUBIN
		 	President and Chief Executive Officer

			
		
	Address:	 	130 Sutter Street, 2nd Floor
		 	San Francisco, CA 94104

 1LIFE HEALTHCARE, INC. 

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT –
SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

	
	KEY HOLDERS:
	
	 /s/ Thomas Ho Lee

	THOMAS HO LEE
	Trustee of the TXL Revocable Trust

  

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

	
	INVESTORS:
	
	CARLYLE PARTNERS VII HOLDINGS, L.P.
	
	BY: TC GROUP VII, L.P., ITS GENERAL PARTNER
	BY: TC GROUP VII, L.L.C., ITS GENERAL PARTNER

 

	
	 /s/ Ram M. Jagannath

	By: Ram M. Jagannath
	Title: Authorized Person

  

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTORS:
	
	OAK INVESTMENT PARTNERS XII, LIMITED PARTNERSHIP
	By: Oak Associates XII, LLC, its General Partner

			
		
	By:	 	 /s/ Ann Lamont

		 	Name: Ann Lamont
		 	Title:   Managing Member

  

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTORS:
	
	DAG VENTURES IV-QP, L.P.
	By:	 	 DAG Ventures Management IV, LLC,
 its General
Partner

		
	By:	 	 /s/ R. Thomas Goodrich

		 	R. Thomas Goodrich, Managing Director
	
	DAG VENTURES IV, L.P.
	By:	 	 DAG Ventures Management IV, LLC,
 its General
Partner

		
	By:	 	 /s/ R. Thomas Goodrich

		 	R. Thomas Goodrich, Managing Director
	
	DAG VENTURES IV-A, LLC
	By:	 	 DAG Ventures Management IV, LLC,
 its
Manager

		
	By:	 	 /s/ R. Thomas Goodrich

		 	R. Thomas Goodrich, Managing Director

  

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

	
	INVESTORS:
	
	BENCHMARK CAPITAL PARTNERS V, L.P.
	as nominee for
	Benchmark Capital Partners V, L.P.
	Benchmark Founders’ Fund V, L.P.
	Benchmark Founders’ Fund V-A, L.P
	Benchmark Founders’ Fund V-B, L.P.
	and related individuals

  

			
	By:	 	Benchmark Capital Management Co. V, L.L.C.
its general partner
		
	By:	 	 /s/ Steven M. Spurlock

		 	Steven M. Spurlock, Managing Member

  

			
	Address:	 	 2965 Woodside Road
 Woodside, CA
94062

  

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTORS:
	
	GV 2013, L.P. 
	By: GV 2013 GP, L.L.C., its General Partner
		
	By:	 	 /s/ Daphne M. Chang

			
	Name: Daphne M. Chang
	Title: Authorized Signatory
	Address:	 	GV 2013, L.P.
		 	1600 Amphitheatre Parkway
		 	Mountain View, CA 94043
		 	With a copy to: notice@gv.com

  

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTORS:
	
	MAVERICK FUND II, LTD.
		
	By:	 	Maverick Capital, Ltd.,
		 	its investment manager
		
	By:	 	 /s/ Ginessa Avile

			
	Name: Ginessa Avile
	Title: Assistant General Counsel
	
	MAVERICK FUND, L.D.C.
		
	By:	 	Maverick Capital, Ltd.,
		 	its investment manager
		
	By:	 	 /s/ Ginessa Avile

			
	Name: Ginessa Avile
	Title: Assistant General Counsel
	
	MAVERICK FUND USA, LTD.
		
	By:	 	Maverick Capital, Ltd.,
		 	its investment manager
		
	By:	 	 /s/ Ginessa Avile

	Name: Ginessa Avile
	Title: Assistant General Counsel

  

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

	
	INVESTORS:
	
	REDMILE CAPITAL OFFSHORE FUND II, LTD.
	
	 /s/ Jeremy Green

	By: Jeremy Green
	Title: Managing Member of the Investment Manager
	
	REDMILE STRATEGIC MASTER FUND, L.P.
	
	 /s/ Jeremy Green

	By: Jeremy Green
	Title: Managing Member of the General Partner and the Investment Manager
	
	REDMILE PRIVATE INVESTMENTS I, LP
	
	 /s/ Jeremy Green

	By: Jeremy Green
	Title: Managing Member of the General Partner and the Management Company
	
	REDMILE PRIVATE INVESTMENTS I AFFILIATES, LP
	
	 /s/ Jeremy Green

	By: Jeremy Green
	Title: Managing Member of the General Partner and the Management Company

  

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTORS:
	
	FIDELITY SELECT PORTFOLIOS: HEALTH CARE PORTFOLIO
		
	By:	 	 /s/ Jonathan Davis

	 Name:
	 	 Jonathan Davis

	 Title:
	 	 Authorized Signatory

	
	FIDELITY SELECT PORTFOLIOS: MEDICAL EQUIPMENT AND SYSTEMS PORTFOLIO
		
	By:	 	 /s/ Jonathan Davis

	 Name:
	 	 Jonathan Davis

	 Title:
	 	 Authorized Signatory

	
	FIDELITY CENTRAL INVESTMENT PORTFOLIOS LLC: FIDELITY HEALTH CARE CENTRAL
FUND
		
	By:	 	 /s/ Jonathan Davis

	 Name:
	 	 Jonathan Davis

	 Title:
	 	 Authorized Signatory

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	FIDELITY ADVISOR SERIES VII: FIDELITY ADVISOR HEALTH CARE FUND
		
	By:	 	 /s/ Jonathan Davis

	Name:	 	Jonathan Davis
	Title:	 	Authorized Signatory
	
	VARIABLE INSURANCE PRODUCTS FUND IV: HEALTH CARE PORTFOLIO
		
	By:	 	 /s/ Jonathan Davis

	Name:	 	Jonathan Davis
	Title:	 	Authorized Signatory

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTORS:	 	
	
	PEG DIGITAL GROWTH FUND II L.P.
	
	By: J.P. Morgan Investment Management Inc.,
	Its: Investment Advisor

			
		
	By:	 	 /s/ Tyler A. Jayroe

		 	Name: Tyler A. Jayroe
		 	Title: Managing Director
	
	AARP INNOVATION FUND L.P.
	
	By: J.P. Morgan Investment Management Inc.,
	Its: Investment Advisor
		
	By:	 	 /s/ Tyler A. Jayroe

		 	Name: Tyler A. Jayroe
		 	Title: Managing Director

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

	
	INVESTORS:
	
	 /s/ Thomas H. Lee

	THOMAS H. LEE

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTORS:

			
		
	By:	 	 /s/ David Kennedy

		 	David Kennedy, Trustee

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 EXHIBIT A 

SCHEDULE OF INVESTORS 

 

					
	 NAME AND
ADDRESS
	  	SERIES A SHARES	 
	 BRICK AND MEG CONWAY
	  	 	100,000	 
	 686 Capp Street

San Francisco, CA 94110
	  			
		
	 TODD HENRICH
	  	 	60,000	 
	 123 Boway Rd

South Salem, NY 10590
	  			
		
	 MING AND MINAKO LEE
	  	 	100,000	 
	 7527 42nd Ave NE

Seattle, WA 98115
	  			
		
	 THOMAS HO LEE, TRUSTEE
OF THE TXL REVOCABLE TRUST
	  	 	400,000	 
	 1 Hawthorne Street, 23D

San Francisco, CA 94105
	  			
		
	 JUSTIN MARTINKOVIC
	  	 	20,000	 
	 810 Jones St #307

San Francisco, CA 94109
	  			
		
	 BRIAN MILFORD
	  	 	10,000	 
	 941 Walnut Avenue

Walnut Creek, CA 94598
	  			
		
	 MOSSER VENTURES
	  	 	20,000	 
	 2826 Octavia Street

San Francisco, CA 94123

Attn: Scott Mosser
	  			
		
	 WILLIAM T. REED AND AMY
DAVIRRO, AS TRUSTEES OF THE 

WILLIAM REED AND AMY
DAVIRRO REVOCABLE TRUST CREATED 

U/D/T DATED JUNE 3, 2014
	  	 	85,000	 
	 148 Elm Avenue

Mill Valley, CA 94941
	  			
		
	 LAIRD S.T. REED REVOCABLE
TRUST
	  	 	100,000	 
	 3352 S. Street N.W.

Washington, DC 20007
	  			
		
	 J. SCOTT SINCLAIR
	  	 	40,000	 
	 128 Wythe Avenue, PHD

Brooklyn, NY 11249
	  			

 A-1 

SCHEDULE OF INVESTORS 

					
	 NAME AND
ADDRESS
	  	SERIES A SHARES	 
	 JAMES WORKMAN
	  	 	50,000	 
	 245 Downey Street

San Francisco, CA 94117
	  			
		
	 EDWARD WU
	  	 	50,000	 
	 77 Hudson Street, Apt. 5

New York, NY 10013
	  			
		
	 LIFEFORCE CAPITAL, LLC
	  	 	25,000	 
	 106 Lincoln Boulevard, Suite 104

San Francisco, CA 94129

Attn: John Noonan
	  			
		
	 LIFEFORCE-CHS
MANAGEMENT-ONE MEDICAL/1LIFE HEALTHCARE LLC
	  	 	70,000	 
	 106 Lincoln Boulevard, Suite 104

San Francisco, CA 94129

Attn: John Noonan
	  			
		
	 TOTAL SERIES A PREFERRED:
	  	 	1,130,000	 
		  	  
	  
	 
		
	 NAME AND
ADDRESS
	  	SERIES B SHARES	 
	 BENCHMARK CAPITAL PARTNERS V, L.P.
	  	 	5,749,630	 
	 2965 Woodside Road

Woodside, CA 94062

Attn: Steve Spurlock
	  			
		
	 KENNEDY FAMILY TRUST
	  	 	348,462	 
	 3930 Washington St.

San Francisco, CA 94118

Attn: David Kennedy
	  			
		
	 SAINTS VENTURES II, L.P.
	  	 	226,500	 
	 2020 Union Street

San Francisco, CA 94123

Attn: Bob Keppler
	  			
		
	 TOTAL SERIES B PREFERRED:
	  	 	6,324,592	 
		  	  
	  
	 

  
 A-2 

SCHEDULE OF INVESTORS 

					
	 NAME AND
ADDRESS
	  	SERIES C SHARES	 
	 DAG VENTURES IV-QP, L.P.
	  	 	3,428,055	 
	 251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  			
		
	 DAG VENTURES IV, L.P.
	  	 	362,285	 
	 251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  			
		
	 DAG VENTURES IV-A, LLC
	  	 	1,082,954	 
	 251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  			
		
	 BENCHMARK CAPITAL PARTNERS V, L.P.
	  	 	3,736,192	 
	 2965 Woodside Road

Woodside, CA 94062

Attn: Steve Spurlock
	  			
		
	 KENNEDY FAMILY TRUST
	  	 	54,148	 
	 3930 Washington St.

San Francisco, CA 94118

Attn: David Kennedy
	  			
		
	 TOTAL SERIES C PREFERRED:
	  	 	8,663,634	 
		  	  
	  
	 

  
 A-3 

SCHEDULE OF INVESTORS 

					
	 NAME AND
ADDRESS
	  	SERIES D SHARES	 
	 OAK INVESTMENT PARTNERS XII,
LIMITED PARTNERSHIP
	  	 	9,519,276	 
	 901 Main Avenue, Suite 600

Norwalk, CT 06851
	  			
		
	 DAG VENTURES IV-QP, L.P.
	  	 	1,377,508	 
	 251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  			
		
	 DAG VENTURES IV, L.P.
	  	 	145,576	 
	 251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  			
		
	 BENCHMARK CAPITAL PARTNERS V, L.P.
	  	 	3,046,168	 
	 2965 Woodside Road

Woodside, CA 94062

Attn: Steve Spurlock
	  			
		
	 THOMAS HO LEE, TRUSTEE
OF THE TXL REVOCABLE TRUST
	  	 	95,192	 
	 1 Hawthorne Street, 23D

San Francisco, CA 94105
	  			
		
	 SHARON A. KNIGHT 1993 TRUST
	  	 	95,192	 
	 4315 21st Street

San Francisco, CA 94114
	  			
		
	 TOTAL SERIES D PREFERRED:
	  	 	14,278,912	 
		  	  
	  
	 

  
 A-4 

SCHEDULE OF INVESTORS 

					
	 NAME AND
ADDRESS
	  	SERIES E SHARES	 
	 MAVERICK FUND, L.D.C.
	  	 	3,064,975	 
	 300 Crescent Court, Suite 1850

Dallas, TX 75201

Tel: (214)880-4040

Fax: (214)880-4042
	  			
		
	 MAVERICK FUND USA, LTD.
	  	 	1,724,781	 
	 300 Crescent Court, Suite 1850

Dallas, TX 75201

Tel: (214)880-4040

Fax: (214)880-4042
	  			
		
	 MAVERICK FUND II, LTD.
	  	 	1,415,256	 
	 300 Crescent Court, Suite 1850

Dallas, TX 75201

Tel: (214)880-4040

Fax: (214)880-4042
	  			
		
	 OAK INVESTMENT PARTNERS X II,
LIMITED PARTNERSHIP
	  	 	4,152,698	 
	 901 Main Avenue, Suite 600

Norwalk, CT 06851
	  			
		
	 BENCHMARK CAPITAL PARTNERS V, L.P.
	  	 	1,358,786	 
	 2965 Woodside Road

Woodside, CA 94062

Attn: Steve Spurlock
	  			
		
	 DAG VENTURES IV-QP, L.P.
	  	 	627,242	 
	 251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  			
		
	 DAG VENTURES IV, L.P.
	  	 	66,287	 
	 251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  			
		
	 TOTAL SERIES E PREFERRED:
	  	 	12,410,025	 

  
 A-5 

SCHEDULE OF INVESTORS 

					
	 
NAME AND
ADDRESS
	  	SERIES F SHARES	 
	 MAVERICK FUND, L.D.C.
	  	 	113,316	 
	 300 Crescent Court, Suite 1850

Dallas, TX 75201

Tel: (214)880-4040

Fax: (214)880-4042
	  			
		
	 MAVERICK FUND USA, LTD.
	  	 	97,501	 
	 300 Crescent Court, Suite 1850

Dallas, TX 75201

Tel: (214)880-4040

Fax: (214)880-4042
	  			
		
	 MAVERICK FUND II, LTD.
	  	 	381,243	 
	 300 Crescent Court, Suite 1850

Dallas, TX 75201

Tel: (214)880-4040

Fax: (214)880-4042
	  			
		
	 OAK INVESTMENT PARTNERS XII,
LIMITED PARTNERSHIP
	  	 	1,304,526	 
	 901 Main Avenue, Suite 600

Norwalk, CT 06851
	  			
		
	 BENCHMARK CAPITAL PARTNERS V, L.P.
	  	 	1,325,406	 
	 2965 Woodside Road

Woodside, CA 94062

Attn: Steve Spurlock
	  			
		
	 DAG VENTURES IV-QP, L.P.
	  	 	611,832	 
	 251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  			
		
	 DAG VENTURES IV, L.P.
	  	 	64,658	 
	 251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  			
		
	 GV 2013, L.P.
	  	 	7,796,967	 
	 Attn: GV Legal Department

1600 Amphitheatre Parkway

Mountain View, CA 94043

Facsimile: 650-887-1790

With a copy to (which shall not constitute notice):

Email: notice@gv.com
	  			
		
	 TOTAL SERIES F PREFERRED:
	  	 	11,695,449	 

  
 A-6 

SCHEDULE OF INVESTORS 

					
	 NAME AND
ADDRESS
	  	SERIES G SHARES	 
	 REDMILE CAPITAL OFFSHORE FUND II, LTD.

Letterman Digital Arts Center

One Letterman Drive, Building D, Suite D3-700

San Francisco, CA 94129
	  	 	759,209	 
		
	 REDMILE STRATEGIC MASTER FUND, L.P.

Letterman Digital Arts Center

One Letterman Drive, Building D, Suite D3-700

San Francisco, CA 94129
	  	 	367,837	 
		
	 REDMILE PRIVATE INVESTMENTS I, LP

Letterman Digital Arts Center

One Letterman Drive, Building D, Suite D3-700

San Francisco, CA 94129
	  	 	659,574	 
		
	 REDMILE PRIVATE INVESTMENTS I AFFILIATES, LP

Letterman Digital Arts Center

One Letterman Drive, Building D, Suite D3-700

San Francisco, CA 94129
	  	 	491,007	 
		
	 FIDELITY SELECT PORTFOLIOS: HEALTH CARE
PORTFOLIO
 Brown Brothers Harriman & Co.

525 Washington Blvd

Jersey City NJ 07310

Attn: Michael Lerman 15th Floor

Corporate Actions
 Email:
michael.lerman@bbh.com
 Fax number: 617 772-2418
	  	 	1,639,892	 
		
	 FIDELITY SELECT PORTFOLIOS: MEDICAL EQUIPMENT
AND SYSTEMS PORTFOLIO
 Brown Brothers Harriman & Co.

525 Washington Blvd

Jersey City NJ 07310

Attn: Michael Lerman 15th Floor

Corporate Actions
 Email:
michael.lerman@bbh.com
 Fax number: 617 772-2418
	  	 	455,526	 

  
 A-7 

SCHEDULE OF INVESTORS 

					
	 NAME AND
ADDRESS
	  	SERIES G SHARES	 
	FIDELITY CENTRAL INVESTMENT PORTFOLIOS LLC: FIDELITY HEALTH CARE CENTRAL FUND	  	 	438,101	 
	 M. Gardiner & Co

c/o JPMorgan Chase Bank, N.A

P.O. Box 35308
 Newark, NJ
07101-8006
 Email: Fidelity.crcs@jpmorgan.com

Jpmorganinformation.services@jpmorgan.com

Fax number: 469-477-1510
	  			
		
	FIDELITY ADVISOR SERIES VII: FIDELITY ADVISOR HEALTH CARE FUND	  	 	322,145	 
	 M. Gardiner & Co

c/o JPMorgan Chase Bank, N.A

P.O. Box 35308
 Newark, NJ
07101-8006
 Email: Fidelity.crcs@jpmorgan.com

Jpmorganinformation.services@jpmorgan.com

Fax number: 469-477-1510
	  			
		
	VARIABLE INSURANCE PRODUCTS FUND IV: HEALTH CARE PORTFOLIO	  	 	181,172	 
	 M. Gardiner & Co

c/o JPMorgan Chase Bank, N.A

P.O. Box 35308
 Newark, NJ
07101-8006
 Email: Fidelity.crcs@jpmorgan.com

Jpmorganinformation.services@jpmorgan.com

Fax number: 469-477-1510
	  			
		
	MAVERICK FUND II, LTD.	  	 	98,371	 
	 300 Crescent Court, Suite 1850

Dallas, TX 75201
 Tel: (214)880-4040
 Fax: (214)880-4042
	  			
		
	OAK INVESTMENT PARTNERS XII, LIMITED PARTNERSHIP	  	 	216,748	 
	 901 Main Avenue, Suite 600

Norwalk, CT 06851
	  			
		
	BENCHMARK CAPITAL PARTNERS V, L.P.	  	 	220,217	 
	 2965 Woodside Road

Woodside, CA 94062
 Attn:
Steve Spurlock
	  			

  
 A-8 

SCHEDULE OF INVESTORS 

					
	 NAME AND
ADDRESS
	  	SERIES G SHARES	 
	DAG VENTURES IV-QP, L.P.	  	 	101,656	 
	 251 Lytton Avenue, Suite 200

Palo Alto, CA 94301
 Tel:
(650) 543-8180
 Fax: (650) 328-2921
	  			
		
	DAG VENTURES IV, L.P.	  	 	10,743	 
	 251 Lytton Avenue, Suite 200

Palo Alto, CA 94301
 Tel:
(650) 543-8180
 Fax: (650) 328-2921
	  			
		
	GV 2013, L.P.	  	 	111,472	 
	 Attn: GV Legal Department

1600 Amphitheatre Parkway

Mountain View, CA 94043

Facsimile: 650-887-1790

 
 With a copy to (which shall not constitute
notice):
 Email: notice@gv.com
	  			
		
	ALLEN PARTNERS FUND I LP	  	 	72,124	 
	 c/o Allen & Company LLC

711 Fifth Avenue
 New
York, NY 10022
 Attn: Peter DiLorio
	  			
		
	JOHN KOSKI	  	 	1,898	 
	 c/o Allen & Company LLC

711 Fifth Avenue
 New
York, NY 10022
	  			
		
	ROBERT LOWE	  	 	1,898	 
	 c/o Allen & Company LLC

711 Fifth Avenue
 New
York, NY 10022
	  			
		
	DIGNITY HEALTH	  	 	455,525	 
	 185 Berry Street, Suite 300

San Francisco, CA 94107

Attn: Lisa Zuckerman
	  			
		
	TOTAL SERIES G PREFERRED:	  	 	6,605,115	 

  
 A-9 

SCHEDULE OF INVESTORS 

					
	 NAME AND
ADDRESS
	  	SERIES H SHARES	 
	PEG DIGITAL GROWTH FUND II L.P.	  	 	5,383,180	 
	 Lawrence Unrein

JP Morgan Asset Management

Private Equity Group
 320
Park Avenue - 15th Floor
 NY1-U016

New York, NY 10022
 Email:
lawrence.m.unrein@jpmorgan.com
  
 and:

 
 Tyler Jayroe

JP Morgan Asset Management

Private Equity Group
 320
Park Avenue - 15th Floor
 NY1-U016

New York, NY 10022
 Email:
tyler.a.jayroe@jpmorgan.com
  
 With a copy to (which shall not constitute
notice):
 Marc A. Persily

Proskauer Rose LLP
 Eleven
Times Square
 New York, NY 10036-8299

Email: mpersily@proskauer.com    
	  			

  
 A-10 

SCHEDULE OF INVESTORS 

					
	 NAME AND
ADDRESS
	  	SERIES H SHARES	 
	 AARP INNOVATION FUND L.P.

Lawrence Unrein
 JP Morgan
Asset Management
 Private Equity Group

320 Park Avenue - 15th Floor

NY1-U016

New York, NY 10022
 Email:
lawrence.m.unrein@jpmorgan.com
  
 and:

 
 Tyler Jayroe

JP Morgan Asset Management

Private Equity Group
 320
Park Avenue - 15th Floor
 NY1-U016

New York, NY 10022
 Email:
tyler.a.jayroe@jpmorgan.com
  
 With a copy to (which shall not constitute
notice):
 Marc A. Persily

Proskauer Rose LLP
 Eleven
Times Square
 New York, NY 10036-8299

Email: mpersily@proskauer.com
	  	 	343,607	 
		
	 LANSDOWNE DEVELOPED MARKETS MASTER FUND
LIMITED
 c/o Lansdowne Partners (UK) LLP

15 Davies Street
 London
W1K 3AG
 United Kingdom

Tel: +44 (0) 20 7290 5500

Email: PE@LansdownePartners.com
  

With a copy to:

Compliance@LansdownePartners.com
	  	 	1,145,358	 
		
	 H. BARTON CO-INVEST FUND II,
LLC
 135 Main Street, Suite 850

San Francisco, CA 94105

Email: harris@bartonam.com, kyle@bartonam.com
	  	 	114,536	 
		
	 FAVREAU 2008 TRUST, DTD
4-10-2008
 c/o Shephard McIlwee Tinglof

9200 Sunset Boulevard, Penthouse 22

Los Angeles, CA 90069

Attn: Jon Favreau
	  	 	114,536	 

  
 A-11 

SCHEDULE OF INVESTORS 

					
	 NAME AND
ADDRESS
	  	SERIES H SHARES	 
	 OAK INVESTMENT PARTNERS XII, LIMITED PARTNERSHIP

901 Main Avenue, Suite 600

Norwalk, CT 06851
	  	 	52,281	 
		
	 GV 2013, L.P.
 Attn:
GV Legal Department
 1600 Amphitheatre Parkway

Mountain View, CA 94043

Facsimile: 650-887-1790

 
 With a copy to (which shall not
constitute notice):
 Email: notice@gv.com
	  	 	28,634	 
		
	 MAVERICK FUND II, LTD.

300 Crescent Court, Suite 1850

Dallas, TX 75201
 Tel: (214)880-4040
 Fax: (214)880-4042
	  	 	28,634	 
		
	 REDMILE CAPITAL OFFSHORE FUND II, LTD.

Letterman Digital Arts Center

One Letterman Drive, Building D, Suite D3-700

San Francisco, CA 94129
	  	 	76,357	 
		
	 REDMILE STRATEGIC MASTER FUND, L.P.

Letterman Digital Arts Center

One Letterman Drive, Building D, Suite D3-700

San Francisco, CA 94129
	  	 	36,995	 
		
	 REDMILE PRIVATE INVESTMENTS I, LP

Letterman Digital Arts Center

One Letterman Drive, Building D, Suite D3-700

San Francisco, CA 94129
	  	 	66,337	 
		
	 REDMILE PRIVATE INVESTMENTS I AFFILIATES, LP

Letterman Digital Arts Center

One Letterman Drive, Building D, Suite D3-700

San Francisco, CA 94129
	  	 	49,383	 
		
	 DIGNITY HEALTH

185 Berry Street, Suite 300

San Francisco, CA 94107
	  	 	4,276	 
		
	 ALLEN PARTNERS FUND I LP

c/o Allen & Company LLC

711 Fifth Avenue
 New
York, NY 10022
 Attn: Peter DiLorio
	  	 	677	 

  
 A-12 

SCHEDULE OF INVESTORS 

					
	 NAME AND
ADDRESS
	  	SERIES H SHARES	 
	 JOHN KOSKI

c/o Allen & Company LLC

711 Fifth Avenue
 New
York, NY 10022
	  	 	18	 
		
	 ROBERT LOWE

c/o Allen & Company LLC

711 Fifth Avenue
 New
York, NY 10022
	  	 	18	 
		  	  
	  
	 
	 TOTAL SERIES H PREFERRED:
	  	 	7,444,827	 
		  	  
	  
	 

  
 A-13 

SCHEDULE OF INVESTORS 

					
	 NAME AND
ADDRESS
	  	SERIES I SHARES	 
	 CARLYLE PARTNERS VII HOLDINGS, L.P.

520 Madison Avenue
 New
York, NY 10022
	  	 	17,699,115	 
		  	  
	  
	 
	 TOTAL:
	  	 	17,699,115	 
		  	  
	  
	 

  
 A-14 

SCHEDULE OF INVESTORSEX-10.2

 Exhibit 10.2 

1LIFE HEALTHCARE, INC. 

AMENDED 2007 EQUITY INCENTIVE PLAN 

ADOPTED BY THE BOARD OF DIRECTORS:
APRIL 24, 2007 
 APPROVED BY THE STOCKHOLDERS:
MAY 4, 2007; 
 AMENDED BY THE BOARD OF
DIRECTORS: JULY 2, 2007 
 APPROVED BY THE
STOCKHOLDERS: JULY 2, 2007 
 AMENDED BY THE
BOARD OF DIRECTORS: NOVEMBER 5, 2008 
 APPROVED
BY THE STOCKHOLDERS: NOVEMBER 5, 2008 
 AMENDED
BY THE BOARD OF DIRECTORS: SEPTEMBER 4, 2009 

APPROVED BY THE STOCKHOLDERS: SEPTEMBER 4, 2009 

AMENDED BY THE BOARD OF DIRECTORS:
APRIL 27, 2010 
 APPROVED BY THE STOCKHOLDERS:
APRIL 27, 2010 
 AMENDED BY THE BOARD
OF DIRECTORS: SEPTEMBER 2, 2011 
 APPROVED BY
THE STOCKHOLDERS: SEPTEMBER 2, 2011 
 AMENDED BY
THE BOARD OF DIRECTORS: FEBRUARY 1, 2012 

APPROVED BY THE STOCKHOLDERS: FEBRUARY 1, 2012 

AMENDED BY THE BOARD OF DIRECTORS:
JUNE 21, 2012 
 APPROVED BY THE STOCKHOLDERS:
JUNE 21, 2012 
 AMENDED BY THE BOARD OF
DIRECTORS: MARCH 5, 2013 
 APPROVED BY THE
STOCKHOLDERS: MARCH 5, 2013 
 AMENDED BY THE
BOARD OF DIRECTORS: APRIL 7, 2014 
 APPROVED
BY THE STOCKHOLDERS: APRIL 7, 2014 
 AMENDED
BY THE BOARD OF DIRECTORS: OCTOBER 1, 2015 

APPROVED BY THE STOCKHOLDERS: NOVEMBER 22, 2015 

AMENDED BY THE BOARD OF DIRECTORS:
MAY 25, 2016 
 TERMINATION DATE: APRIL 24, 2017 

 

	1.	 GENERAL. 

(a) Eligible Stock Award Recipients. The persons eligible to receive Stock Awards are Employees, Directors and Consultants. 

(b) Available Stock Awards. The Plan provides for the grant of the following Stock Awards: (i) Incentive Stock Options,
(ii) Nonstatutory Stock Options, (iii) Restricted Stock Awards, (iv) Restricted Stock Unit Awards, and (v) Stock Appreciation Rights. 

(c) Purpose. The Company, by means of the Plan, seeks to secure and retain the services of the group of persons eligible to
receive Stock Awards as set forth in Section 1(a), to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate, and to provide a means by which such eligible recipients may be given an
opportunity to benefit from increases in value of the Common Stock through the granting of Stock Awards. 
  

	2.	 ADMINISTRATION. 

(a) Administration by Board. The Board shall administer the Plan unless and until the Board delegates administration of the Plan
to a Committee, as provided in Section 2(c). 

  
 1. 

 (b) Powers of Board. The Board shall have the power, subject to, and within
the limitations of, the express provisions of the Plan: 
 (i) To determine from time to time (A) which of the persons eligible
under the Plan shall be granted Stock Awards; (B) when and how each Stock Award shall be granted; (C) what type or combination of types of Stock Award shall be granted; (D) the provisions of each Stock Award granted (which need not be
identical), including the time or times when a person shall be permitted to receive cash or Common Stock pursuant to a Stock Award; (E) the number of shares of Common Stock with respect to which a Stock Award shall be granted to each such
person; and (F) the Fair Market Value applicable to a Stock Award. 
 (ii) To construe and interpret the Plan and Stock Awards
granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner
and to the extent it shall deem necessary or expedient to make the Plan or Stock Award fully effective. 
 (iii) To settle all
controversies regarding the Plan and Stock Awards granted under it. 
 (iv) To accelerate the time at which a Stock Award may first be
exercised or the time during which a Stock Award or any part thereof will vest in accordance with the Plan, notwithstanding the provisions in the Stock Award stating the time at which it may first be exercised or the time during which it will vest.

 (v) To suspend or terminate the Plan at any time. Suspension or termination of the Plan shall not impair rights and obligations
under any Stock Award granted while the Plan is in effect except with the written consent of the affected Participant. 
 (vi) To
amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, relating to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A of the Code and/or to bring the Plan or
Stock Awards granted under the Plan into compliance therewith, subject to the limitations, if any, of applicable law. However, except as provided in Section 11(a) relating to Capitalization Adjustments, to the extent required by applicable law,
stockholder approval shall be required for any amendment of the Plan that either (i) materially increases the number of shares of Common Stock available for issuance under the Plan, (ii) materially expands the class of individuals eligible
to receive Stock Awards under the Plan, (iii) materially increases the benefits accruing to Participants under the Plan or materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan,
(iv) materially extends the term of the Plan, or (v) expands the types of Stock Awards available for issuance under the Plan. Except as provided above, rights under any Stock Award granted before amendment of the Plan shall not be impaired
by any amendment of the Plan unless (i) the Company requests the consent of the affected Participant, and (ii) such Participant consents in writing.  

(vii) To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to
satisfy the requirements of Section 422 of the Code regarding Incentive Stock Options. 
 (viii) To approve forms of Stock Award
Agreements for use under the Plan and to amend the terms of any one or more Stock Awards, including, but not limited to, amendments to provide terms more favorable than previously provided in the Stock Award Agreement, subject to any specified
limits in the Plan that are not subject to Board discretion; provided however, that, the rights under any 

  
 2. 

 
Stock Award shall not be impaired by any such amendment unless (i) the Company requests the consent of the affected Participant, and (ii) such Participant consents in writing.
Notwithstanding the foregoing, subject to the limitations of applicable law, if any, and without the affected Participant’s consent, the Board may amend the terms of any one or more Stock Awards if necessary to maintain the qualified status of
the Stock Award as an Incentive Stock Option or to bring the Stock Award into compliance with Section 409A of the Code and the related guidance thereunder. 

(ix) Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests
of the Company and that are not in conflict with the provisions of the Plan or Stock Awards. 
 (x) To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States. 

(xi) To effect, at any time and from time to time, with the consent of any adversely affected Optionholder, (1) the reduction of
the exercise price of any outstanding Option under the Plan, (2) the cancellation of any outstanding Option under the Plan and the grant in substitution therefor of (A) a new Option under the Plan or another equity plan of the Company
covering the same or a different number of shares of Common Stock, (B) a Restricted Stock Award, (C) a Stock Appreciation Right, (D) Restricted Stock Unit, (E) cash and/or (F) other valuable consideration (as determined by
the Board, in its sole discretion), or (3) any other action that is treated as a repricing under generally accepted accounting principles; provided, however, that no such reduction or cancellation may be effected if it is determined, in
the Company’s sole discretion, that such reduction or cancellation would result in any such outstanding Option becoming subject to the requirements of Section 409A of the Code. 

(c) Delegation to Committee. The Board may delegate some or all of the administration of the Plan to a Committee or Committees.
If administration of the Plan is delegated to a Committee, the Committee shall have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to
delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board shall thereafter be to the Committee or subcommittee), subject, however, to such
resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some
or all of the powers previously delegated. 
 (d) Delegation to an Officer. The Board may delegate to one or more Officers the
authority to do one or both of the following: (i) designate Employees who are not Officers to be recipients of Options (and, to the extent permitted by applicable law, other Stock Awards) and the terms thereof, and (ii) determine the
number of shares of Common Stock to be subject to such Stock Awards granted to such Employees; provided, however, that the Board resolutions regarding such delegation shall specify the total number of shares of Common Stock that may be
subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself. Notwithstanding the foregoing, the Board may not delegate authority to an Officer to determine the Fair Market Value of the
Common Stock pursuant to Section 15(t) below. 
 (e) Effect of Board’s Decision. All determinations,
interpretations and constructions made by the Board in good faith shall not be subject to review by any person and shall be final, binding and conclusive on all persons. 

  
 3. 

 (f) Arbitration. Any dispute or claim concerning any Stock Awards granted (or
not granted) pursuant to the Plan or any disputes or claims relating to or arising out of the Plan shall be fully, finally and exclusively resolved by binding and confidential arbitration conducted pursuant to the Commercial Arbitration Rules of the
American Arbitration Association the rules of Judicial Arbitration and Mediation Services, Inc. (“JAMS”) in California. The Company shall pay all arbitration fees. In addition to any other relief, the arbitrator may award to the prevailing
party recovery of its attorneys’ fees and costs. By accepting a Stock Award, Participants and the Company waive their respective rights to have any such disputes or claims tried by a judge or jury. 

 

	3.	 SHARES SUBJECT TO THE PLAN.

 (a) Subject to Section 11(a) relating to Capitalization Adjustments, the aggregate number of shares of
Common Stock of the Company that may be issued pursuant to Stock Awards after the Effective Date shall not exceed 17,319,254 shares (the “Share Reserve”). For clarity, the limitation in this Section 3(a) is a limitation
in the number of shares of Common Stock that may be issued pursuant to the Plan. Accordingly, this Section 3(a) does not limit the granting of Stock Awards except as provided in Section 7(a). Furthermore, if a Stock Award (i) expires
or otherwise terminates without having been exercised in full or (ii) is settled in cash (i.e., the holder of the Stock Award receives cash rather than stock), such expiration, termination or settlement shall not reduce (or otherwise
offset) the number of shares of Common Stock that may be issued pursuant to the Plan. 
 (b) If any shares of Common Stock issued
pursuant to a Stock Award are forfeited back to the Company because of the failure to meet a contingency or condition required to vest such shares in the Participant, then the shares which are forfeited shall revert to and again become available for
issuance under the Plan. Also, any shares reacquired by the Company pursuant to Section 10(g) or as consideration for the exercise of an Option shall again become available for issuance under the Plan. Notwithstanding the provisions of this
Section 3(b), any such shares shall not be subsequently issued pursuant to the exercise of Incentive Stock Options. 
 (c)
Incentive Stock Option Limit. Notwithstanding anything to the contrary in this Section 3(c), subject to the provisions of Section 11(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock
that may be issued pursuant to the exercise of Incentive Stock Options shall be equal to two times the Share Reserve.  
 (d)
Source of Shares. The stock issuable under the Plan shall be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market. 

 

	4.	 ELIGIBILITY. 

(a) Eligibility for Specific Stock Awards. Incentive Stock Options may be granted only to employees of the Company or a
“parent corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections 424(e) and (f) of the Code). Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and
Consultants. 
 (b) Ten Percent Stockholders. A Ten Percent Stockholder shall not be granted an Incentive Stock Option unless
the exercise price of such Option is at least one hundred ten percent (110%) of the Fair Market Value of the Common Stock on the date of grant and the Option is not exercisable after the expiration of five (5) years from the date of grant. 

  
 4. 

 (c) Consultants. A Consultant shall not be eligible for the grant of a
Stock Award if, at the time of grant, either the offer or the sale of the Company’s securities to such Consultant is not exempt under Rule 701 promulgated under the Securities Act (“Rule 701”) because of the nature of
the services that the Consultant is providing to the Company, because the Consultant is not a natural person, or because of any other provision of Rule 701, unless the Company determines that such grant need not comply with the requirements of Rule
701 and will satisfy another exemption under the Securities Act as well as comply with the securities laws of all other relevant jurisdictions. 
  

	5.	 OPTION PROVISIONS. 

Each Option shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. All Options shall be
separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates shall be issued for shares of Common Stock purchased on exercise of each type
of Option. If an Option is not specifically designated as an Incentive Stock Option, then the Option shall be a Nonstatutory Stock Option. The provisions of separate Options need not be identical; provided, however, that each Option Agreement
shall include (through incorporation of provisions hereof by reference in the Option Agreement or otherwise) the substance of each of the following provisions: 

(a) Term. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, no Option shall be exercisable after
the expiration of ten (10) years from the date of its grant or such shorter period specified in the Option Agreement. 
 (b)
Exercise Price. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, the exercise price of each Option shall be not less than one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the
Option on the date the Option is granted. Notwithstanding the foregoing, an Option may be granted with an exercise price lower than one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the Option if such Option is
granted pursuant to an assumption or substitution for another option in a manner consistent with the provisions of Section 424(a) of the Code (whether or not such options are Incentive Stock Options). 

(c) Consideration. The purchase price of Common Stock acquired pursuant to the exercise of an Option shall be paid, to the extent
permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board shall have the authority to grant Options that do not permit all of the following methods of
payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. The permitted methods of payment are as follows: 

(i) by cash, check, bank draft or money order payable to the Company; 

(ii) pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the
stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds; 

(iii) by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock; 

  
 5. 

 (iv) by a “net exercise” arrangement pursuant to which the Company will
reduce the number of shares of Common Stock issued upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; provided, however, that the Company shall accept a cash or
other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued; provided, further, that shares of Common Stock will no
longer be outstanding under an Option and will not be exercisable thereafter to the extent that (A) shares are used to pay the exercise price pursuant to the “net exercise,” (B) shares are delivered to the Participant as a result of
such exercise, and (C) shares are withheld to satisfy tax withholding obligations; or 
 (v) in any other form of legal
consideration that may be acceptable to the Board. 
 (d) Transferability of Options. The Board may, in its sole discretion,
impose such limitations on the transferability of Options as the Board shall determine. In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options shall apply: 

(i) Restrictions on Transfer. An Option shall not be transferable except by will or by the laws of descent and distribution and
shall be exercisable during the lifetime of the Optionholder only by the Optionholder; provided, however, that the Board may, in its sole discretion, permit transfer of the Option to such extent as permitted by Rule 701 promulgated under the
Securities Act at the time of the grant of the Option and in a manner consistent with applicable tax and securities laws upon the Optionholder’s request. 

(ii) Domestic Relations Orders. Notwithstanding the foregoing, an Option may be transferred pursuant to a domestic relations
order, provided, however, that an Incentive Stock Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. 

(iii) Beneficiary Designation. Notwithstanding the foregoing, the Optionholder may, by delivering written notice to the Company,
in a form provided by or otherwise satisfactory to the Company, designate a third party who, in the event of the death of the Optionholder, shall thereafter be the beneficiary of an Option with the right to exercise the Option and receive the Common
Stock or other consideration resulting from the Option exercise. 
 (e) Vesting of Options Generally. The total number of
shares of Common Stock subject to an Option may vest and therefore become exercisable in periodic installments that may or may not be equal. The Option may be subject to such other terms and conditions on the time or times when it may or may not be
exercised (which may be based on the satisfaction of performance goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options may vary. The provisions of this Section 5(e) are subject to any Option
provisions governing the minimum number of shares of Common Stock as to which an Option may be exercised. 
 (f) Termination of
Continuous Service. Except as otherwise provided in the applicable Option Agreement or other agreement between the Optionholder and the Company, in the event that an Optionholder’s Continuous Service terminates (other than for Cause or upon
the Optionholder’s death or Disability), the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination of Continuous Service) but only within such period
of time ending on the earlier of (i) the date three (3) months following the termination of the Optionholder’s Continuous Service (or such longer or shorter period specified in the Option Agreement, which period shall not be less than
thirty (30) days unless such termination is for Cause), or (ii) the expiration of the term of the Option as set forth in the Option Agreement. If, after termination of Continuous Service, the Optionholder does not exercise his or her
Option within the time specified herein or in the Option Agreement (as applicable), the Option shall terminate. 

  
 6. 

 (g) Extension of Termination Date. An Optionholder’s Option Agreement may
provide that if the exercise of the Option following the termination of the Optionholder’s Continuous Service (other than for Cause or upon the Optionholder’s death or Disability) would be prohibited at any time solely because the issuance
of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option shall terminate on the earlier of (i) the expiration of a period of three (3) months after the termination of the
Optionholder’s Continuous Service during which the exercise of the Option would not be in violation of such registration requirements, or (ii) the expiration of the term of the Option as set forth in the Option Agreement. 

(h) Disability of Optionholder. In the event that an Optionholder’s Continuous Service terminates as a result of the
Optionholder’s Disability, the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination of Continuous Service), but only within such period of time
ending on the earlier of (i) the date twelve (12) months following such termination of Continuous Service (or such longer or shorter period specified in the Option Agreement, which period shall not be less than six (6) months), or
(ii) the expiration of the term of the Option as set forth in the Option Agreement. If, after termination of Continuous Service, the Optionholder does not exercise his or her Option within the time specified herein or in the Option Agreement
(as applicable), the Option shall terminate. 
 (i) Death of Optionholder. In the event that (i) an Optionholder’s
Continuous Service terminates as a result of the Optionholder’s death, or (ii) the Optionholder dies within the period (if any) specified in the Option Agreement after the termination of the Optionholder’s Continuous Service for a
reason other than death, then the Option may be exercised (to the extent the Optionholder was entitled to exercise such Option as of the date of death) by the Optionholder’s estate, by a person who acquired the right to exercise the Option by
bequest or inheritance or by a person designated as the beneficiary of the Option upon the Optionholder’s death, but only within the period ending on the earlier of (i) the date eighteen (18) months following the date of death (or
such longer or shorter period specified in the Option Agreement, which period shall not be less than six (6) months), or (ii) the expiration of the term of such Option as set forth in the Option Agreement. If, after the Optionholder’s
death, the Option is not exercised within the time specified herein or in the Option Agreement (as applicable), the Option shall terminate. If the Optionholder designates a third party beneficiary of the Option in accordance with
Section 5(d)(iii), then upon the death of the Optionholder such designated beneficiary shall have the sole right to exercise the Option and receive the Common Stock or other consideration resulting from the Option exercise. 

(j) Termination for Cause. Except as explicitly provided otherwise in an Optionholder’s Option Agreement, in the event that
an Optionholder’s Continuous Service is terminated for Cause, the Option shall terminate upon the termination date of such Optionholder’s Continuous Service, and the Optionholder shall be prohibited from exercising his or her Option from
and after the time of such termination of Continuous Service. 
 (k) Non-Exempt
Employees. No Option granted to an Employee that is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, shall be first exercisable for any shares of Common Stock until
at least six months following the date of grant of the Option. The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of
an Option will be exempt from his or her regular rate of pay. 
 (l) Early Exercise. The Option may, but need not, include a
provision whereby the Optionholder may elect at any time before the Optionholder’s Continuous Service terminates to exercise the Option as to any part or all of the shares of Common Stock subject to the Option prior to the full vesting of the
Option. Subject to the “Repurchase Limitation” in Section 10(l), any unvested shares of 

  
 7. 

 
Common Stock so purchased may be subject to a repurchase option in favor of the Company or to any other restriction the Board determines to be appropriate. Provided that the “Repurchase
Limitation” in Section 10(k) is not violated, the Company shall not be required to exercise its repurchase option until at least six (6) months (or such longer or shorter period of time required to avoid classification of the Option
as a liability for financial accounting purposes) have elapsed following exercise of the Option unless the Board otherwise specifically provides in the Option Agreement. 

(m) Right of Repurchase. Subject to the “Repurchase Limitation” in Section 10(k), the Option may include a
provision whereby the Company may elect to repurchase all or any part of the vested shares of Common Stock acquired by the Optionholder pursuant to the exercise of the Option. Provided that the “Repurchase Limitation” in Section 10(k)
is not violated, the Company shall not be required to exercise its repurchase option until at least six (6) months (or such longer or shorter period of time necessary to avoid classification of the Option as a liability for financial accounting
purposes) have elapsed following exercise of the Option unless otherwise specifically provided in the Option Agreement. 
 (n)
Right of First Refusal. The Option may include a provision whereby the Company may elect to exercise a right of first refusal following receipt of notice from the Optionholder of the intent to transfer all or any part of the shares of Common
Stock received upon the exercise of the Option. Such right of first refusal shall be subject to the “Repurchase Limitation” in Section 10(k). Except as expressly provided in this Section 5(n) or in the Option Agreement, such
right of first refusal shall otherwise comply with any applicable provisions of the Bylaws of the Company. 
  

	6.	 PROVISIONS OF STOCK AWARDS OTHER
THAN OPTIONS. 

 (a) Restricted Stock Awards. Each Restricted Stock Award
Agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. To the extent consistent with the Company’s Bylaws, at the Board’s election, shares of Common Stock may be (x) held in
book entry form subject to the Company’s instructions until any restrictions relating to the Restricted Stock Award lapse; or (y) evidenced by a certificate, which certificate shall be held in such form and manner as determined by the
Board. The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical; provided, however, that each Restricted Stock
Award Agreement shall include (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions: 

(i) Consideration. A Restricted Stock Award may be awarded in consideration for (A) past or future services actually or to
be rendered to the Company or an Affiliate, or (B) any other form of legal consideration that may be acceptable to the Board in its sole discretion and permissible under applicable law. 

(ii) Vesting. Subject to the “Repurchase Limitation” in Section 10(k), shares of Common Stock awarded under the
Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board. 

(iii) Termination of Participant’s Continuous Service. In the event a Participant’s Continuous Service terminates, the
Company may receive via a forfeiture condition, any or all of the shares of Common Stock held by the Participant which have not vested as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement. 

  
 8. 

 (iv) Transferability. Rights to acquire shares of Common Stock under the
Restricted Stock Award Agreement shall be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board shall determine in its sole discretion, so long as Common Stock
awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement. 
 (b)
Restricted Stock Unit Awards. Each Restricted Stock Unit Award Agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. The terms and conditions of Restricted Stock Unit Award Agreements
may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical, provided, however, that each Restricted Stock Unit Award Agreement shall include (through incorporation of
the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions: 
 (i)
Consideration. At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award.
The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board in its sole discretion and
permissible under applicable law. 
 (ii) Vesting. At the time of the grant of a Restricted Stock Unit Award, the Board may
impose such restrictions or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate. 

(iii) Payment. A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any
combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. 

(iv) Additional Restrictions. At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may
impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award. 

(v) Dividend Equivalents. Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock
Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock
Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all the terms and conditions of the underlying Restricted Stock
Unit Award Agreement to which they relate. 
 (vi) Termination of Participant’s Continuous Service. Except
as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant’s termination of Continuous Service.  

(vii) Compliance with Section 409A of the Code. Notwithstanding anything to the contrary set forth herein, any
Restricted Stock Unit Award granted under the Plan that is not exempt from the requirements of Section 409A of the Code shall contain such provisions so that such Restricted Stock Unit Award will comply with the requirements of
Section 409A of the Code. Such restrictions, if any, shall be determined by the Board and contained in the Restricted Stock Unit Award Agreement evidencing such Restricted Stock Unit Award. For example, such restrictions may include, without
limitation, a requirement that any Common Stock that is to be issued in a year following the year in which the Restricted Stock Unit Award vests must be issued in accordance with a fixed pre-determined
schedule. 

  
 9. 

 (c) Stock Appreciation Rights. Each Stock Appreciation Right Agreement shall
be in such form and shall contain such terms and conditions as the Board shall deem appropriate. Stock Appreciation Rights may be granted as stand-alone Stock Awards or in tandem with other Stock Awards. The terms and conditions of Stock
Appreciation Right Agreements may change from time to time, and the terms and conditions of separate Stock Appreciation Right Agreements need not be identical; provided, however, that each Stock Appreciation Right Agreement shall include
(through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions: 

(i) Term. No Stock Appreciation Right shall be exercisable after the expiration of ten (10) years from the date of grant or
such shorter period specified in the Stock Appreciation Right Agreement. 
 (ii) Strike Price. Each Stock Appreciation Right
will be denominated in shares of Common Stock equivalents. The strike price of each Stock Appreciation Right granted as a stand-alone or tandem Stock Award shall not be less than one hundred percent (100%) of the Fair Market Value of the Common
Stock equivalents subject to the Stock Appreciation Right on the date of grant. 
 (iii) Calculation of Appreciation. The
appreciation distribution payable on the exercise of a Stock Appreciation Right will be not greater than an amount equal to the excess of (A) the aggregate Fair Market Value (on the date of the exercise of the Stock Appreciation Right) of a
number of shares of Common Stock equal to the number of shares of Common Stock equivalents in which the Participant is vested under such Stock Appreciation Right, and with respect to which the Participant is exercising the Stock Appreciation Right
on such date, over (B) the strike price that will be determined by the Board on the date of grant. 
 (iv) Vesting. At the
time of the grant of a Stock Appreciation Right, the Board may impose such restrictions or conditions to the vesting of such Stock Appreciation Right as it, in its sole discretion, deems appropriate. 

(v) Exercise. To exercise any outstanding Stock Appreciation Right, the Participant must provide written notice of exercise to
the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such Stock Appreciation Right. 

(vi) Non-Exempt Employees. No Stock Appreciation Right granted to an Employee that is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, shall be first exercisable for any shares of Common Stock until at least six months following the date of grant of the Stock
Appreciation Right. The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of a Stock Appreciation Right will be exempt
from his or her regular rate of pay. 
 (vii) Payment. The appreciation distribution in respect to a Stock Appreciation Right
may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Stock Appreciation Right Agreement evidencing such Stock Appreciation Right. 

  
 10. 

 (viii) Termination of Continuous Service. In the event that a
Participant’s Continuous Service terminates (other than for Cause), the Participant may exercise his or her Stock Appreciation Right (to the extent that the Participant was entitled to exercise such Stock Appreciation Right as of the date of
termination) but only within such period of time ending on the earlier of (A) the date three (3) months following the termination of the Participant’s Continuous Service (or such longer or shorter period specified in the Stock
Appreciation Right Agreement, which period shall not be less than thirty (30) days unless such termination is for Cause), or (B) the expiration of the term of the Stock Appreciation Right as set forth in the Stock Appreciation Right
Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Stock Appreciation Right within the time specified herein or in the Stock Appreciation Right Agreement (as applicable), the Stock Appreciation Right
shall terminate. 
 (ix) Termination for Cause. Except as explicitly provided otherwise in an Participant’s Stock
Appreciation Right Agreement, in the event that a Participant’s Continuous Service is terminated for Cause, the Stock Appreciation Right shall terminate upon the termination date of such Participant’s Continuous Service, and the
Participant shall be prohibited from exercising his or her Stock Appreciation Right from and after the time of such termination of Continuous Service. 

(x) Compliance with Section 409A of the Code. Notwithstanding anything to the contrary set forth
herein, any Stock Appreciation Rights granted under the Plan that are not exempt from the requirements of Section 409A of the Code shall contain such provisions so that such Stock Appreciation Rights will comply with the requirements of
Section 409A of the Code. Such restrictions, if any, shall be determined by the Board and contained in the Stock Appreciation Right Agreement evidencing such Stock Appreciation Right. For example, such restrictions may include, without
limitation, a requirement that a Stock Appreciation Right that is to be paid wholly or partly in cash must be exercised and paid in accordance with a fixed pre-determined schedule. 

 

	7.	 LIMITED TRANSFERABILITY OF OPTIONS,
UNDERLYING SECURITIES AND STOCK AWARDS. 

(a) Restrictions on Transfer. Without limitation of any other restrictions on transfer set forth in this Plan, each Optionholder
shall be bound by the following restrictions: 
 (i) No Optionholder shall Transfer any Stock without the prior written consent of the
Company, upon a duly authorized action of its Board, or an authorized representative thereof with authority delegated by the Board, (i) to individuals, companies or any other form of entity identified by the Company as a current or potential
competitor, either directly or indirectly, or considered by the Company to be unfriendly, or any affiliate of such person or entity, as determined in good faith by the Board, or to any Special Purpose Entity; or (ii) if such Transfer increases
the risk of the Company having a class of security held of record by five hundred or more persons, as described in Section 12(g) of the Exchange Act, and Rule 12g5-1 promulgated thereunder, or otherwise
requiring the company to register any class of securities under the Exchange Act; or (iii) if such Transfer would result in the loss of any federal or state securities law exemption relied upon by the Company in connection with the initial
issuance of Shares or the issuance of any other securities; or (iv) if such Transfer is facilitated in any manner by any public posting, message board, trading portal, internet site intended to facilitate secondary transfers of securities, or
(v) if such Transfer is to be effected in a brokered transaction; or (vi) if such Transfer represents a Transfer of less than all of the shares then held by the stockholder and its affiliates or is to be made to more than a single
transferee. 
 (ii) No Optionholder may list, sell or offer to sell or otherwise trade in Company securities on any private market
place or securities exchange, including without limitation on SecondMarket or SharesPost (each, a “Private Market Exchange”), until such time that a court of competent jurisdiction or appropriate regulatory authority has issued a ruling or
endorsed the activities of such Private Market Exchange as compliant with applicable securities law to the Company’s reasonable satisfaction. 

  
 11. 

 (iii) The foregoing restrictions on transfer with respect to the Stock shall lapse
upon the earlier of (i) immediately prior to the closing of an IPO or (ii) the consummation of a Liquidation Event. 
 (iv)
Any Transfer, or purported Transfer, of Stock not made in strict compliance with this Section 7 shall be null and void, shall not be recorded on the books of the Company and shall not be recognized by the Company. 

(b) Continuing Restrictions on Transfer for Certain Optionholders. Without limiting any right or remedy of the Company to enforce
Section 7(a) of the Plan, to the extent any person who was an Optionholder prior to the adoption of Section 7(a) does not agree to be bound by or otherwise comply with the restriction in Section 7(a) hereof, the restrictions on
transfer set forth in Sections 5(d) and 6(a)(iv)of the Plan or in the Restricted Stock Unit Award Agreement or in the Stock Appreciation Right Agreement will continue to apply to such Optionholder. 

(c) Transferee Obligations. Each person (other than the Company) to whom Stock is transferred in accordance with this
Section 7 must, as a condition precedent to the validity of such transfer, be required to acknowledge in writing to the Company that such person is bound by the provisions of this Section 7 (and the form of amended stock option agreement
and exercise notice), as may be amended from time to time in the Company’s sole discretion, to the same extent that such Stock would be so subject if retained by the Optionholder; and there shall be no further Transfer of such Stock except in
accordance with this Section 7. 
  

	8.	 CONDITIONS UPON ISSUANCE OF
SHARES. 

 (a) Legal Compliance. Shares shall not be issued pursuant to the exercise of an
Option or other Stock Award unless the exercise of such Option or other Stock Award and the issuance and delivery of such Shares shall comply with Applicable Laws and shall be further subject to the approval of counsel for the Company with respect
to such compliance. 
 (b) Investment Representations. As a condition to the exercise of an Option or other Stock Award and if,
in the opinion of counsel for the Company, such a representation is required, the Administrator may require the person exercising such Option or other Stock Award to represent and warrant at the time of any such exercise that: 

i. the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares; and 

ii. the Transferee will not sell, transfer, pledge or otherwise dispose of any Shares received by Transferee unless and until (a) such
Shares are subsequently registered under the Securities Act and any applicable state securities laws, or (b) (i) an exemption from such registration is available thereunder, and (ii) Transferee has notified the Company of the proposed
transfer and has furnished the Company with an opinion of counsel in a form reasonably satisfactory to the Company that such transfer will not require registration of such shares under the Securities Act. 

  
 12. 

	9.	 COVENANTS OF THE COMPANY.

 (a) Availability of Shares. During the terms of the Stock Awards, the Company shall keep available at
all times the number of shares of Common Stock reasonably required to satisfy such Stock Awards. 
 (b) Securities Law
Compliance. The Company shall seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the
Stock Awards; provided, however, that this undertaking shall not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable
efforts, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company shall be relieved from any
liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained. 

(c) No Obligation to Notify. The Company shall have no duty or obligation to any holder of a Stock Award to advise such holder as
to the time or manner of exercising such Stock Award. Furthermore, the Company shall have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of a Stock Award or a possible period in which the Stock
Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award. 
  

	10.	 MISCELLANEOUS. 

(a) Use of Proceeds from Sales of Common Stock. Proceeds from the sale of shares of Common Stock pursuant to Stock Awards shall
constitute general funds of the Company. 
 (b) Corporate Action Constituting Grant of Stock Awards. Corporate action
constituting a grant by the Company of a Stock Award to any Participant shall be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing
the Stock Award is communicated to, or actually received or accepted by, the Participant. 
 (c) Stockholder Rights. No
Participant shall be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Stock Award unless and until such Participant has satisfied all requirements for exercise of the
Stock Award pursuant to its terms and the Participant shall not be deemed to be a stockholder of record until the issuance of the Common Stock pursuant to such exercise has been entered into the books and records of the Company. 

(d) No Employment or Other Service Rights. Nothing in the Plan, any Stock Award Agreement or any other instrument executed
thereunder or in connection with any Stock Award granted pursuant thereto shall confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or shall affect
the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the
Company or an Affiliate, or (iii) the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the
case may be. 

  
 13. 

 (e) Incentive Stock Option $100,000 Limitation. To the extent that the
aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any
Affiliates) exceeds one hundred thousand dollars ($100,000), the Options or portions thereof that exceed such limit (according to the order in which they were granted) shall be treated as Nonstatutory Stock Options, notwithstanding any contrary
provision of the applicable Option Agreement(s). 
 (f) Investment Assurances. The Company may require a Participant, as a
condition of exercising or acquiring Common Stock under any Stock Award, (i) to give written assurances satisfactory to the Company as to the Participant’s knowledge and experience in financial and business matters and/or to employ a
purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and
risks of exercising the Stock Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant’s own account and not with any
present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, shall be inoperative if (x) the issuance of the shares upon the exercise or acquisition
of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (y) as to any particular requirement, a determination is made by counsel for the Company that such
requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or
appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock. 

(g) Withholding Obligations. To the extent provided by the terms of a Stock Award Agreement, the Company may, in its sole
discretion, satisfy any federal, state or local tax withholding obligation relating to a Stock Award by any of the following means (in addition to the Company’s right to withhold from any compensation paid to the Participant by the Company) or
by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock
Award; provided, however, that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of the Stock Award as a
liability for financial accounting purposes); (iii) withholding payment from any amounts otherwise payable to the Participant; (iv) withholding cash from a Stock Award settled in cash; or (v) by such other method as may be set forth in the
Stock Award Agreement. 
 (h) Electronic Delivery. Any reference herein to a “written” agreement or document shall
include any agreement or document delivered electronically or posted on the Company’s intranet. 
 (i) Deferrals. To the
extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Stock Award may be deferred and may
establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will be made in accordance with Section 409A of the Code. Consistent with Section 409A of the Code, the Board may provide for
distributions while a Participant is still an employee. The Board is authorized to make deferrals of Stock Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the
Participant’s termination of employment or retirement, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law. 

  
 14. 

 (j) Compliance with Section 409A. To the extent that the
Board determines that any Stock Award granted hereunder is subject to Section 409A of the Code, the Stock Award Agreement evidencing such Stock Award shall incorporate the terms and conditions necessary to avoid the consequences specified in
Section 409A(a)(1) of the Code. To the extent applicable, the Plan and Stock Award Agreements shall be interpreted in accordance with Section 409A of the Code and Department of Treasury regulations and other interpretive guidance issued
thereunder, including without limitation any such regulations or other guidance that may be issued or amended after the Effective Date. Notwithstanding any provision of the Plan to the contrary, in the event that following the Effective Date the
Board determines that any Stock Award may be subject to Section 409A of the Code and related Department of Treasury guidance (including such Department of Treasury guidance as may be issued after the Effective Date), the Board may adopt such
amendments to the Plan and the applicable Stock Award Agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Board determines are necessary or
appropriate to (1) exempt the Stock Award from Section 409A of the Code and/or preserve the intended tax treatment of the benefits provided with respect to the Stock Award, or (2) comply with the requirements of Section 409A of
the Code and related Department of Treasury guidance. 
 (k) Compliance with Exemption Provided by Rule 12h-1(f). If: (i) the aggregate of the number of Optionholders and the number of holders of all other outstanding compensatory employee stock options to purchase shares of Common Stock equals or exceeds
five hundred (500), and (ii) the assets of the Company at the end of the Company’s most recently completed fiscal year exceed $10 million, then the following restrictions shall apply during any period during which the Company does not
have a class of its securities registered under Section 12 of the Exchange Act and is not required to file reports under Section 15(d) of the Exchange Act: (A) the Options and, prior to exercise, the shares of Common Stock acquired
upon exercise of the Options may not be transferred until the Company is no longer relying on the exemption provided by Rule 12h-1(f) promulgated under the Exchange Act (“Rule 12h-1(f)”), except: (1) as permitted by Rule 701(c) promulgated under the Securities Act, (2) to a guardian upon the disability of the Optionholder, or (3) to an executor upon the death
of the Optionholder (collectively, the “Permitted Transferees”); provided, however, the following transfers are permitted: (i) transfers by the Optionholder to the Company, and (ii) transfers in connection
with a change of control or other acquisition involving the Company, if following such transaction, the Options no longer remain outstanding and the Company is no longer relying on the exemption provided by Rule
12h-1(f); provided further, that any Permitted Transferees may not further transfer the Options; (B) except as otherwise provided in (A) above, the Options and shares of Common Stock acquired
upon exercise of the Options are restricted as to any pledge, hypothecation, or other transfer, including any short position, any “put equivalent position” as defined by Rule 16a-1(h) promulgated
under the Exchange Act, or any “call equivalent position” as defined by Rule 16a-1(b) promulgated under the Exchange Act by the Optionholder prior to exercise of an Option until the Company is no
longer relying on the exemption provided by Rule 12h-1(f); and (C) at any time that the Company is relying on the exemption provided by Rule 12h-1(f), the Company
shall deliver to Optionholders (whether by physical or electronic delivery or written notice of the availability of the information on an internet site) the information required by Rule 701(e)(3), (4), and (5) promulgated under the Securities
Act every six (6) months, including financial statements that are not more than one hundred eighty (180) days old; provided, however, that the Company may condition the delivery of such information upon the Optionholder’s
agreement to maintain its confidentiality. 
 (l) Repurchase Limitation. The terms of any repurchase option shall be specified
in the Stock Award Agreement. The repurchase price for vested shares of Common Stock shall be the Fair Market Value of the shares of Common Stock on the date of repurchase. The repurchase price for unvested shares of Common Stock shall be the lower
of (i) the Fair Market Value of the shares of Common Stock on the date of repurchase or (ii) their original purchase price. However, the Company 

  
 15. 

 
shall not exercise its repurchase option until at least six (6) months (or such longer or shorter period of time necessary to avoid classification of the Stock Award as a liability for
financial accounting purposes) have elapsed following delivery of shares of Common Stock subject to the Stock Award, unless otherwise specifically provided by the Board. 
  

	11.	 ADJUSTMENTS UPON CHANGES IN
COMMON STOCK; OTHER CORPORATE EVENTS. 

(a) Capitalization Adjustments. In the event of a Capitalization Adjustment, the Board shall proportionately and appropriately
adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to
Section 3(c), and (iii) the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. 

(b) Dissolution or Liquidation. Except as otherwise provided in the Stock Award Agreement, in the event of a dissolution or
liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to the Company’s right of repurchase) shall terminate immediately prior to the completion
of such dissolution or liquidation, and the shares of Common Stock subject to the Company’s repurchase option may be repurchased by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service,
provided, however, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously
expired or terminated) before the dissolution or liquidation is completed but contingent on its completion. 
 (c) Corporate
Transaction. The following provisions shall apply to Stock Awards in the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate
and the holder of the Stock Award or unless otherwise expressly provided by the Board at the time of grant of a Stock Award. 
 (i)
Stock Awards May Be Assumed. Except as otherwise stated in the Stock Award Agreement, in the event of a Corporate Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent
company) may assume or continue any or all Stock Awards outstanding under the Plan or may substitute similar stock awards for Stock Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the
stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Stock Awards may be assigned by the Company to the successor of the
Company (or the successor’s parent company, if any), in connection with such Corporate Transaction. A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of a Stock Award or substitute
a similar stock award for only a portion of a Stock Award. The terms of any assumption, continuation or substitution shall be set by the Board in accordance with the provisions of Section 2. 

(ii) Stock Awards Not Assumed. Except as otherwise stated in the Stock Award Agreement or as otherwise determined by the Board in
its sole discretion, in the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such
outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted, the vesting of such Stock Awards (and, if applicable, the time at which such Stock Award may be exercised) shall not be accelerated and
such Stock Awards (other than a Stock Award consisting of vested and outstanding shares of Common Stock not subject to the Company’s right of repurchase) shall terminate if not exercised (if applicable) prior to the closing of the Corporate
Transaction; provided, however, that any reacquisition or repurchase rights held by the Company with respect to such Stock Awards shall not terminate and may continue to be exercised notwithstanding the Corporate Transaction. 

  
 16. 

 (iii) Payment for Stock Awards in Lieu of Exercise. Notwithstanding the
foregoing, in the event a Stock Award will terminate if not exercised prior to the closing of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Stock Award may or need not exercise such Stock Award but
will receive a payment, in such form as may be determined by the Board, equal in value to the excess, if any, of (A) the value of the property the holder of the Stock Award would have received upon the exercise of the Stock Award, over
(B) any exercise price payable by such holder in connection with such exercise; provided, however, if the Company has not provided written notice to a holder of Stock Awards informing them of the pending termination of such Stock
Awards’ as a result of the events described in Section 9(c)(ii) with a reasonable time period for such Holder to exercise such Stock Awards prior to termination, such holder of Stock Awards will receive the payments such holder would
otherwise be entitled to under this Section 9(c)(iii) automatically and without any further necessary action by the holder of the Stock Awards. 

(d) Change in Control. A Stock Award may be subject to additional acceleration of vesting and exercisability upon or after a
Change in Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and the Participant, but in the absence of such provision, no such
acceleration shall occur. 
  

	12.	 TERMINATION OR SUSPENSION OF THE
PLAN. 

 (a) Plan Term. The Board may suspend or terminate the Plan at any time. Unless
sooner terminated by the Board pursuant to Section 2, the Plan shall automatically terminate on the day before the tenth (10th) anniversary of the earlier of (i) the date the Plan is adopted by the Board, or (ii) the date the Plan is
approved by the stockholders of the Company. No Stock Awards may be granted under the Plan while the Plan is suspended or after it is terminated. 

(b) No Impairment of Rights. Suspension or termination of the Plan shall not impair rights and obligations under any Stock Award
granted while the Plan is in effect except with the written consent of the affected Participant. 
  

	13.	 EFFECTIVE DATE OF PLAN.

 This Plan shall become effective on the Effective Date.  

 

	14.	 CHOICE OF LAW. 

The law of the State of California shall govern all questions concerning the construction, validity and interpretation of this Plan, without
regard to that state’s conflict of laws rules. 
  

	15.	 DEFINITIONS. As used in the Plan, the following definitions shall apply to the
capitalized terms indicated below: 

 (a) “Administrator” means the Board or any of
its Committees as shall be administering the Plan in accordance with Section 2 hereof. 
 (b) “Applicable
Laws” means the requirements relating to the administration of stock option plans under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is
listed or quoted and the applicable laws of any other country or jurisdiction where Options or other Stock Awards are granted under the Plan. 

  
 17. 

 (c) “Affiliate” means, at the time of determination, any
“parent” or “majority-owned subsidiary” of the Company, as such terms are defined in Rule 405 of the Securities Act. The Board shall have the authority to determine the time or times at which “parent” or
“majority-owned subsidiary” status is determined within the foregoing definition. 
 (d) “Board”
means the Board of Directors of the Company. 
 (e) “Capitalization Adjustment” means any change that is made
in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company (through merger, consolidation, reorganization,
recapitalization, reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other transaction not involving the receipt of
consideration by the Company). Notwithstanding the foregoing, the conversion of any convertible securities of the Company shall not be treated as a transaction “without the receipt of consideration” by the Company. 

(f) “Cause” means with respect to a Participant, the occurrence of any of the following events:
(i) such Participant’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) such Participant’s attempted commission of, or
participation in, a fraud or act of dishonesty against the Company; (iii) such Participant’s intentional, material violation of any contract or agreement between the Participant and the Company or of any statutory duty owed to the Company;
(iv) such Participant’s unauthorized use or disclosure of the Company’s confidential information or trade secrets; or (v) such Participant’s gross misconduct. The determination that a termination of the Participant’s
Continuous Service is either for Cause or without Cause shall be made by the Company in its sole discretion. Any determination by the Company that the Continuous Service of a Participant was terminated by reason of dismissal without Cause for the
purposes of outstanding Stock Awards held by such Participant shall have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose. 

(g) “Change in Control” means the occurrence, in a single transaction or in a series of related transactions, of
any one or more of the following events: 
 (i) any Exchange Act Person becomes the Owner, directly or indirectly, of securities of
the Company representing more than fifty percent (50%) of the combined voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in
Control shall not be deemed to occur (A) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company’s securities in a transaction or series of
related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities or (B) solely because the level of Ownership held by any Exchange Act Person (the “Subject
Person”) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a
Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities
that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to
occur; 

  
 18. 

 (ii) there is consummated a merger, consolidation or similar transaction involving
(directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either
(A) outstanding voting securities representing more than fifty percent (50%) of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than fifty percent (50%) of the
combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company
immediately prior to such transaction; 
 (iii) there is consummated a sale, lease, exclusive license or other disposition of all or
substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more
than fifty percent (50%) of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately
prior to such sale, lease, license or other disposition; or 
 (iv) individuals who, on the date this Plan is adopted by the Board,
are members of the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election)
of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board. 

For the avoidance of doubt, the term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively
for the purpose of changing the domicile of the Company. 
 Notwithstanding the foregoing or any other provision of this Plan, the
definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Stock Awards subject to such agreement;
provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply. 

(h) “Code” means the Internal Revenue Code of 1986, as amended. 

(i) “Committee” means a committee of one (1) or more Directors to whom authority has been delegated by the
Board in accordance with Section 2(c). 
 (j) “Common Stock” means the common stock of the Company. 

(k) “Company” means 1Life Healthcare, Inc., a Delaware corporation. 

(l) “Consultant” means any person, including an advisor, who is (i) engaged by the Company or an Affiliate
to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a
fee for such service, shall not cause a Director to be considered a “Consultant” for purposes of the Plan.  

  
 19. 

 (m) “Continuous Service” means that the Participant’s
service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant
or Director or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant’s service with the Company or an Affiliate, shall not terminate a Participant’s
Continuous Service; provided, however, if the Entity for which a Participant is rendering service ceases to qualify as an Affiliate, as determined by the Board in its sole discretion, such Participant’s Continuous Service shall be
considered to have terminated on the date such Entity ceases to qualify as an Affiliate. For example, a change in status from an employee of the Company to a consultant of an Affiliate or to a Director shall not constitute an interruption of
Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party’s sole discretion, may determine whether Continuous Service shall be considered interrupted in the case of any leave of
absence approved by that party, including sick leave, military leave or any other personal leave. Notwithstanding the foregoing, a leave of absence shall be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent
as may be provided in the Company’s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. 

(n) “Corporate Transaction” means the occurrence, in a single transaction or in a series of related
transactions, of any one or more of the following events: 
 (i) the consummation of a sale or other disposition of all or
substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Company and its Subsidiaries; 

(ii) the consummation of a sale or other disposition of at least ninety percent (90%) of the outstanding securities of the Company; 

(iii) the consummation of a merger, consolidation or similar transaction following which the Company is not the surviving corporation;
or 
 (iv) the consummation of a merger, consolidation or similar transaction following which the Company is the surviving corporation
but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of
securities, cash or otherwise. 
 (o) “Director” means a member of the Board. 

(p) “Disability” means the inability of a Participant to engage in any substantially gainful activity by reason
of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than twelve (12) months, and shall be determined by the
Board on the basis of such medical evidence as the Board deems warranted under the circumstances. 
 (q) “Effective
Date” means the effective date of this Plan, which is the earlier of (i) the date that this Plan is first approved by the Company’s stockholders, or (ii) the date this Plan is adopted by the Board. 

(r) “Employee” means any person employed by the Company or an Affiliate. However, service solely as a Director,
or payment of a fee for such services, shall not cause a Director to be considered an “Employee” for purposes of the Plan. 

  
 20. 

 (s) “Entity” means a corporation, partnership, limited
liability company or other entity. 
 (t) “Exchange Act” means the Securities Exchange Act of 1934, as
amended. 
 (u) “Exchange Act Person” means any natural person, Entity or “group”
(within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” shall not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any
Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to an offering of such
securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or “group” (within
the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date of the Plan as set forth in Section 13, is the Owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%)
of the combined voting power of the Company’s then outstanding securities. 
 (v) “Fair Market Value”
means, as of any date, the value of the Common Stock determined by the Board in compliance with Section 409A of the Code or, in the case of an Incentive Stock Option, in compliance with Section 422 of the Code. 

(w) “Immediate Family” as used herein shall mean spouse, parents, grandparents, lineal descendants, siblings and
lineal descendants of siblings of the stockholder making such transfer. 
 (x) “Incentive Stock Option” means
an Option that qualifies as an “incentive stock option” within the meaning of Section 422 of the Code and the regulations promulgated thereunder. 

(y) “IPO” means the first sale of the Company’s Common Stock to the general public pursuant to a
registration statement under the Securities Act. 
 (z) “Liquidation Event” shall have the meaning as defined
in Section 3(a), Article IV of the Amended and Restated Certificate of Incorporation of the Company, as the same may be amended and/or restated from time to time. 

(aa) “Nonstatutory Stock Option” means an Option that does not qualify as an Incentive Stock Option. 

(bb) “Officer” means any person designated by the Company as an officer. 

(cc) “Option” means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock
granted pursuant to the Plan. 
 (dd) “Option Agreement” means a written agreement between the Company and an
Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement shall be subject to the terms and conditions of the Plan. 

(ee) “Optionholder” means a person to whom an Option or other Stock Award is granted pursuant to the Plan or, if
applicable, such other person who holds an outstanding Option or other Stock Award. 

  
 21. 

 (ff) “Own,” “Owned,”
“Owner,” “Ownership” A person or Entity shall be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if
such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities. 

(gg) “Participant” means a person to whom a Stock Award is granted pursuant to the Plan or, if applicable, such
other person who holds an outstanding Stock Award. 
 (hh) “Permitted Transfer” shall mean, and be restricted
to, any Transfer of a share of Stock by a Qualified Stockholder (i) held either during such stockholder’s lifetime or on death by will or intestacy to such stockholder’s Immediate Family or to any custodian or trustee for the account
of such stockholder or such stockholder’s Immediate Family or to any limited partnership of which the stockholder, members of such stockholder’s Immediate Family or any trust for the account of such stockholder or such stockholder’s
Immediate Family will be the general or limited partner(s) of such partnership, or (ii) to any other Qualified Stockholder of the Company, or (iii) to the Company; provided, however, that in the case of (i) or (ii), the party
to which such shares of Stock are transferred agrees in writing to be bound by the terms of this Plan (including Section 7) and any other applicable restrictions on such shares of Stock. 

(ii) “Plan” means this 1Life Healthcare, Inc. 2007 Equity Incentive Plan. 

(jj) “Qualified Stockholder” shall mean (a) any Optionholder under this Plan; or (b) any transferee of
shares of Stock received in a Transfer that constitutes a Permitted Transfer. 
 (kk) “Restricted Stock Award”
means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(a). 
 (ll)
“Restricted Stock Award Agreement” means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award. Each Restricted Stock Award Agreement
shall be subject to the terms and conditions of the Plan. 
 (mm) “Restricted Stock Unit Award”
means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(b). 

(nn) “Restricted Stock Unit Award Agreement” means a written agreement between the Company and a
holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement shall be subject to the terms and conditions of the Plan. 

(oo) “Securities Act” means the Securities Act of 1933, as amended. 

(pp) “Share” means a share of the Common Stock, as adjusted in accordance with Section 11 hereof. 

(qq) “Special Purpose Entity” shall mean an entity that holds or would hold only securities of the Company or
has or would have a class or series of security holders with beneficial interests primarily in securities of the Company (including for such purpose an entity that holds cash and/or cash equivalents intended to purchase such securities). 

  
 22. 

 (rr) “Stock” means and includes all shares of Common Stock
issued and outstanding at the relevant time plus (a) all shares of Common Stock that may be issued upon exercise of any options, warrants and other rights of any kind that are then exercisable, and (b) all shares of Common Stock that may
be issued upon conversion of (i) any convertible securities, including, without limitation, Preferred Stock and debt securities then outstanding that are by their terms then convertible into or exchangeable for Common Stock or (ii) any
such convertible securities issuable upon exercise of outstanding options, warrants or other rights that are then exercisable. 
 (ss)
“Stock Appreciation Right” means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 6(c). 

(tt) “Stock Appreciation Right Agreement” means a written agreement between the Company and a holder of a Stock
Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement shall be subject to the terms and conditions of the Plan. 

(uu) “Stock Award” means any right to receive Common Stock granted under the Plan, including an Incentive Stock
Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, or a Stock Appreciation Right. 
 (vv)
“Stock Award Agreement” means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant. Each Stock Award Agreement shall be subject to the terms and conditions of
the Plan. 
 (ww) “Subsidiary” means, with respect to the Company, (i) any corporation of which more than
fifty percent (50%) of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation shall
have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct
or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than fifty percent (50%) . 

(xx) “Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to Section 424(d) of
the Code) stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or any Affiliate 

(yy) “Transfer” and “Transferred” mean and include any sale, assignment, transfer,
conveyance, hypothecation or other transfer or disposition of a share of Stock or any legal or beneficial interest in such share, whether or not for value and whether voluntary or involuntary or by operation of law, including without limitation, a
transfer of a share of Stock to a broker or other nominee (regardless of whether there in is a corresponding change in beneficial ownership); provided, however, that a Permitted Transfer shall not be considered a Transfer. 

  
 23.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]